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Nijmegen Breakage Syndrome (NBS), a rare autosomal recessive disorder typically 
caused by mutations in NBS1 gene, is characterized by immunodeficiency and a strong 
predisposition to cancer. Studies revealed that NBS1 plays an important role in 
maintaining genome stability, but the underlying mechanism is controversial and elusive. 
Our study used NBS cells derived from NBS patients with 657del5 mutation in NBS1 
gene as well as normal cells with wild type NBS1 gene to examine the roles of NBS1 in 
maintaining genome stability. Our results showed that NBS1 was involved in ataxia-
telangiectasia mutated (ATM)- and ataxia-telangiectasia and Rad3-related (ATR)-
dependent DNA damage signaling pathways. NBS1 deficiency led to a decrease in the 
phosphorylation level of  ATM and ATR as well as their downstream targets, including 
histone H2AX, p53, Chk1 and Chk2. The inefficiency in activating DNA damage 
signaling pathway led to multiple defects in cellular responses towards DNA damage. 
BrdU proliferation assay revealed a delay of NBS cells in inhibiting DNA synthesis after 
Doxorubicin (Dox) treatment. In addition, under high concentration of 1μM Dox, NBS 
cells exhibited 15% ~ 25% lower level of apoptosis compared to their normal 
counterparts, indicating a resistance to Dox treatment.  
Accelerated telomere shortening was also observed in NBS fibroblasts, consistent with an 
earlier onset of cellular replicative senescence in vitro. This abnormality may be due to 
the shelterin protein telomeric binding factor 2 (TRF2) which was found to be 
upregulated in NBS fibroblasts. However, both accelerated telomere shortening and 
upregulation of TRF2 were not observed in NBS B-lymphocytes, although these cells 
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showed earlier occurrence of senescence-associated apoptosis. These results suggest that 
NBS1 deficiency exerts different regulatory effects on fibroblasts and B-lymphocytes 
even with the same type of gene mutation. Dysregulation of telomere shortening rate and 
TRF2 expression level in NBS fibroblasts led to frequent telomere end-to-end fusions and 
cellular aneuploidy. 
Collectively, our results suggest a possible mechanism that NBS1 deficiency 
simultaneously affects ATM- and ATR-dependent DNA damage signaling and TRF2-
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1.1 NBS and NBS1 protein 
NBS is a rare autosomal recessive disorder which was first delineated in 1981 by C. 
Weemaes and colleagues. NBS is characterized by immunodeficiency, microcephaly, 
growth retardation, congenital malformations and a strong predisposition to malignancies, 
especially to B-cell lymphoma (The International Nijmegen Breakage Syndrome Study 
Group 2000). The main causes of death in NBS patients are lymphoid malignancy and 
infectious complications of immunodeficiency (Resnick, Kondratenko et al. 2002). A 
study of 55 NBS patients showed that 40% of them developed cancer before 21 years old 
(The International Nijmegen Breakage Syndrome Study Group 2000).  
The underlying gene mutated in NBS, NBS1, was cloned in 1998 with chromosomal 
location 8q21 (Varon, Vissinga et al. 1998). NBS1 gene is 50 kb in size and consists of 16 
exons. NBS1 is expressed ubiquitously and the expression level is higher in the testis 
(Kobayashi, Antoccia et al. 2004). Mutation screening of NBS1 gene has identified six 
distinct mutations in NBS patients, including 657del5, 698del4, 835del4, 842insT, 
1142delC and 976C>T (Varon, Vissinga et al. 1998). Among all these patients, 90% of 
them are homozygous for the 657del5 mutation. 657del5 mutation causes two truncated 
proteins because of premature termination at codon 219, a N-terminal and a C-terminal 
species with relative molecular weight of 26 KD and 70 KD respectively (Figure 1.1B) 
(Maser, Zinkel et al. 2001). The mutation of NBS1 gene leads to pleiotropic phenotypes 
of NBS cells in vitro, such as hyper-sensitivity to ionizing radiation (IR), impaired cell 
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cycle checkpoints, decreased homologous recombination, accelerated telomere 




Figure 1.1 The structure of NBS1 (modified from (Tauchi, Matsuura et al. 2002)). A. 
Schematic diagram representing the wild type NBS1 structure. B. Schematic diagram 
representing the truncated NBS1 N-terminus and C-terminus structure caused by internal 




The normal NBS1 gene encodes a 754 amino acid protein that contains three functional 
regions (Figure 1.1A): the N-terminal DNA damage recognition region, the signal 
transduction region and the C-terminal MRE11 binding region (Kobayashi, Antoccia et al. 
2004). The N-terminal DNA damage recognition region contains a forkhead-associated 
(FHA) domain and a BRCA1 C-terminus (BRCT) domain which are widely conserved in 
eukaryotes. FHA and BRCT domains involve in regulation of cell cycle checkpoints and 
DNA damage repair. The FHA domain is generally thought to mediate protein-protein 
 3 
 
interactions (Durocher, Henckel et al. 1999). It is reported that the FHA/BRCT domain is 
essential for binding to the phosphorylated histone H2AX, following which the MRE11 
and RAD50 are recruited to the vicinity of DNA damage foci (Kobayashi, Tauchi et al. 
2002). The central region includes several SQ motifs that could be phosphorylated by 
ATM or  ATR kinase in response to DNA damage, especially at serine (Ser) 278 and 
Ser343. Following phosphorylation, NBS1 undergoes a conformational change that 
makes NBS1 as an adaptor in DNA damage signaling pathway. Adaptor NBS1 positions 
NBS1-binding proteins in a manner such that could be phosphorylated by ATM/ATR 
(Yazhi, Zhao et al. 2006). Phosphorylation of NBS1 is essential to execute its 
downstream cellular functions, such as cell cycle checkpoint control and DNA damage 
repair (Iijima, Komatsu et al. 2004; Kobayashi, Antoccia et al. 2004; Zhang, Zhou et al. 
2006). Mutation at the phosphorylation sites partially abrogates its cellular functions in 
DNA damage responses (Lim, Kim et al, 2000). The C-terminus of NBS1 contains the 
region that binds to MRE11. The binding of NBS1 to MRE11 is necessary for the 
recruitment of MRE11 and RAD50 from cytoplasm to nucleus, thus forming the MRN 
complex, a central player in many aspects of the cellular response towards DNA double 
strand breaks (DSBs) (Assenmacher and Hopfner 2004). In addition to MRE11, the C-
terminus of NBS1 is able to attract other factors to DNA damage foci to amplify and 
propagate the original signal to multiple DNA damage response pathways (Bradbury and 




1.2 MRN complex 
MRN complex consists of three subunits, MRE11, RAD50 and NBS1. This complex is a 
main player in cellular response to DSBs in many aspects, including DSB detection and 
processing, DSB-activated cell cycle checkpoint and telomere maintenance 
(Assenmacher and Hopfner 2004). This broad range of cellular functions of MRN 
complex is explained by the multiple enzymatic and non-enzymatic activities of its 
components.  
The MRE11 component is a nuclease with ssDNA endonuclease, 3’ to 5’ ssDNA 
exonuclease, dsDNA exonuclease and hairpin opening activities in vitro (Rupnik, 
Lowndes et al. 2010). These nuclease activities are dependent on the presence of NBS1 
(Paull and Gellert 1999). RAD50 is a member of the Structural Maintenance of 
Chromosome family proteins with ATPase activity. The central region of RAD50 
contains a large coiled-coil structure that allows itself fold back via a “hinge” region 
(Rupnik, Lowndes et al. 2010). The third component of MRN complex, NBS1, plays 
important roles in regulating complex functions. Firstly, NBS1 is required for the 
localization of MRE11 and RAD50 to nucleus. Secondly, NBS1 stimulates the activities 
of MRE11 and RAD50. Thirdly, NBS1 is also essential for the assembly of MRN 
complex at sites of DNA damage in nucleus (Carney, Maser et al. 1998; Horejsi, Falck et 
al. 2004; Rupnik, Lowndes et al. 2010).  
Electron microscopy and scanning force microscopy revealed a striking architecture of 
MRN complex. The MRN complex exhibits as a bipolar structure with a head and two 
tails (Figure 1.2). The head is composed of two RAD50 ATPase domains along with a 
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MRE11 dimer. Although not directly imaged, NBS1 is suggested as part of the head and 
binds to MRE11 molecules by biophysical data (Assenmacher and Hopfner 2004). The 
tails presents as anti-parallel coiled-coil structure which can form interlocked hook 





Figure 1.2 Structural model of the MRN complex (modified from (Assenmacher and 
Hopfner 2004)). MRE11 binds to RAD50, adjacent to the RAD50 ATPase domains. NBS1 is 
suggested binding to MRE11.  
 
 
MRN complex is required to maintain genome stability. Null mutation of any component 
of MRN complex is lethal in higher eukaryotes (Luo, Yao et al. 1999; Yamaguchi-Iwai, 
Sonoda et al. 1999; Zhu, Petersen et al. 2001). Hypomorphic mutations in NBS1 and 
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MRE11 cause human genetic diseases, NBS and ataxia-telangiectasia like disease 
(ATLD), respectively (Matsuura, Tauchi et al. 1998; Stewart, Maser et al. 1999). 
Hypomorphic RAD50 mutant mice (RAD50 (S/S) mice) show growth defects and cancer 
predisposition, and die with complete bone marrow depletion as a consequence of 
hematopoietic stem cell failure (Bender, Sikes et al. 2002). Thus, disturbance of MRN 
complex activity has profound effects on genome stability, indicating the importance of 





1.3 ATM and ATR kinases 
ATM and ATR belong to a superfamily of protein kinases which contain a domain at their 
carboxyl termini with motifs that is characteristic of the lipid kinase phosphatidylinositol 
3-kinase (PI3K), thus they are named ‘PI3K-like protein kinases’ (PIKKs). The 
mammalian members of PIKK family respond to various cellular stresses by 
phosphorylating other proteins in the corresponding pathways, therefore affecting 
numerous cellular processes depending on the spectrum of their targets (Shiloh 2003). 
ATM and ATR are at the central of DNA damage signaling pathways. About 25 substrates 
of ATM and ATR have been identified, and many of them have been revealed as 
candidates in DNA damage signaling pathway that play a role in cell cycle checkpoint, 
DNA damage repair or apoptosis (Matsuoka, Ballif et al. 2007).  
The importance of ATM and ATR in DNA damage signaling pathway has been 
manifested in human genetic disorder ataxia-telangiectasia (A-T) and ATR-Seckle 
syndrome, which are caused by the mutation of ATM and ATR gene, respectively (Stiff, 
Reis et al. 2005). However, ATM and ATR have different functional roles as manifested 
by the pathological symptoms of A-T and  ATR-Seckle syndrome (Table 1). The 
functional differences between ATM and ATR are also reflected in the genetically 
modified mice. ATM knockout mice are viable though infertile and growth-retarded (Xu, 
Ashley et al. 1996). In contrast, ATR knockout mice show early embryonic death in 
development subsequent to the blastocyst stage. ATR-null blastocyst cells only continue 
growth for 2 days before dying of caspase-dependent apoptosis (Brown and Baltimore 
2000). These results indicate that ATR plays a vital role for normal cell growth, while 
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ATM is not essential for cell viability.  
Although in the same family, ATM and ATR respond to different types of DNA damage 
stimuli. Due to this fact, it is generally thought that ATM and ATR orchestrate DNA 
damage response separately in response to specific types of DNA damage. While ATM 
mainly responds to DSBs, ATR primarily reacts to single strand breaks (SSBs) and stalled 
replication forks (Shiloh 2001; Matsuoka, Ballif et al. 2007). However, recent studies 
suggest that ATM- and ATR-mediated signaling pathways are highly interconnected. 
ATM and ATR communicate with each other to coordinate and modulate the cellular 
outputs in respond to DNA strand breaks and stalled replication forks (Hurley and Bunz 
2007).   
Many studies have revealed that NBS1 is involved in both ATM- and ATR-mediated 
DNA damage signaling pathways (Lim, Kim et al. 2000; Stiff, Reis et al. 2005). It is 
worth to note that the characteristics of NBS disease almost encompass those of A-T and 
ATR-Seckle (Table 1). Notably, A-T disease shares the clinical characteristics, such as 
hypersensitivity to IR, immunodeficiency and cancer predisposition, with NBS (Tauchi, 
Matsuura et al. 2002). Moreover, the cellular features of A-T cells also partly overlap 
with those of NBS cells, like chromosome instabilities, abnormal cell cycle checkpoints 
and accelerated telomere shortening (Kobayashi, Antoccia et al. 2004). Besides A-T 
disease, ATR-Seckle syndrome also shares several clinical symptoms with NBS, namely 
microcephaly and characteristic facial appearance (Stiff, Reis et al. 2005). The 
similarities between A-T/ATR-Seckle syndrome and NBS further imply that NBS1 and 
ATM/ATR work in the same or similar signaling pathway.  
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Table 1. Comparison of clinical signs with NBS, A-T, ATLD and ATR-Seckle syndrome 
 
Clinical symptom NBS ATLD A-T ATR-Seckle 
syndrome 
Ataxia - + + - 
Growth retardation + NK - - 
Characteristic facial appearance + - - + 
Microcephaly  + - - + 
Hypersensitivity to IR + + + - 
Immunodeficiency + - + - 
Ovarian failure  + NK + - 
Mental retardation  - - - + 
Neuronal degeneration  - NK + - 
Telangiectasia  - - + - 
Cancer predisposition  + NK + - 
Cryptorchidism  - - - + 
Low birth weight - NK - + 
‘+’ means clinical positive; ‘-’ means clinical negative, ‘NK’ means not known. 
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1.4 DNA damage response 
DNA is susceptible to a multitude of damaging agents, including intracellular reactive 
metabolites and extracellular harmful factors, such as environmental chemicals, IR or UV 
light (Essers, Vermeulen et al. 2006). DNA damage caused by these damaging agents is a 
serious threat to cellular homeostasis as it compromises genome stability and integrity. Of 
the many types of DNA lesions, DSBs are particularly cytotoxic. If failed to be repaired, 
some of the DNA lesions may induce cell malignancy transformation (Shiloh 2006). Thus, 
cells have evolved a complex signaling network to regulate DNA damage response and 
maintain genome stability.  
1.4.1 DNA damage sensing 
DNA damage response begins with “sensor” proteins that sense DNA lesions/chromatin 
alterations after DNA damage induction. This process is characterized by rapid formation 
of DNA damage foci composed of recruited DNA damage response proteins (Shiloh 
2006). The recruitment of these proteins follows a temporal order.  
Histone H2AX is the first protein that is phosphorylated by ATM and possibly ATR 
shortly after induction of DSBs. The phosphorylated state of histone H2AX, γ-H2AX, 
immediately forms foci and co-localizes with other proteins that respond to DSBs, such 
as MRN complex (Kobayashi, Antoccia et al. 2004). MRN complex is the first candidate 
that is recruited to the sites of DSB foci (Tauchi, Matsuura et al. 2002). The recruitment 
of MRN complex follows two steps. Firstly, NBS1 interacts with γ-H2AX through the 
FHA/BRCT domain rather than directly binds to damaged DNA (Kobayashi, Tauchi et al. 
2002). The interaction between NBS1 and γ-H2AX is essential for the following 
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recruitment of MRE11/RAD50 from cytoplasm to the vicinity of DSB damage sites, thus 
forming the functional MRN complex. In the second step, MRN complex switches to a 
mode of direct association with damaged DNA by the DNA binding region within 
MRE11/RAD50 (Tauchi, Matsuura et al. 2002; Kobayashi, Antoccia et al. 2004). 
However, it has also been reported that NBS1 recognition of DSB foci does not require 
the modification of H2AX (γ-H2AX). Using microbeam radiation, it was found that the 
recruitment of NBS1 to DNA damage sites was not impaired in H2AX-/- mice (Celeste, 
Fernandez-Capetillo et al. 2003). MDC1 (mediator of DNA damage checkpoint protein) 
and 53BP1 (p53 binding protein 1) are the following DSBs sensors that bind to DNA 
damage foci. The recruitment of additional proteins and the repeated protein-protein 
interaction stabilize the DSB foci and thus facilitate the transduction of damage signals to 
transducers (Shiloh 2006).   
1.4.2 DNA damage mediating - ATM and ATR activation 
Imaging analysis has demonstrated that ATM is also present at DSB foci together with 
MRN and other DSB damage sensors (Bekker-Jensen, Lukas et al. 2006), although the 
hierarchical association of ATM and MRN to the sites of damage foci has been rather 
elusive. Since NBS1 is known to be phosphorylated by ATM in response to DSB-
inducing agents, ATM must function upstream of NBS1 (Lim, Kim et al. 2000). However, 
recent findings place NBS1 upstream of ATM and redefine NBS1 an activator in addition 
to a sensor (Shiloh 2006). It has been found that in response to DNA DSBs, MRN 
complex binds tightly to both DNA and ATM, implicating the role of MRN in the 
recruitment of ATM to damaged DNA (Matsuoka, Ballif et al. 2007). During this process, 
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dimeric ATM is autophosphorylated and become active monomers (Dupre, Boyer-
Chatenet et al. 2006). But the remaining question is whether the recruitment of ATM to 
DSB foci must precede its activation. Further studies on the ATM activation mechanism 
will clarify this point.  
ATR, which mainly responds to SSBs and stalled replication forks, is also found present 
together with MRN and BRCA1 at single-stranded DNA ends (Shiloh 2006). NBS1 is not 
only phosphorylated by ATM but also a downstream target of ATR (Stiff, Reis et al. 
2005). However, whether NBS1 functions upstream of ATR and modulate its activation is 
not known. Recent findings suggest a positive role of NBS1 in the activation of ATR. In 
response to hydroxyurea (HU), a chemotherapeutic drug that induces replication stalling, 
the  ATR-dependent phosphorylation of Chk1 and replication protein A (RPA) was 
defective in NBS1 deficient cells (Stiff, Reis et al. 2005; Manthey, Opiyo et al. 2007). 
Furthermore, the other ATR-dependent events, such as ubiquitination of FANCD2 and 
restart of stalled replication forks, were also impaired in NBS1 deficient cells (Zhou, Lim 
et al. 2006). 
Recent data suggests that the activation of ATM and ATR could be affected by each other. 
In response to IR-induced DSBs, ATR is also robustly activated in addition to ATM. This 
activation of ATR is ATM-dependent (Cuadrado, Martinez-Pastor et al. 2006; Myers and 
Cortez 2006). ATM could induce the generation of RPA-coated single-stranded DNA, 
which is essential for the following recruitment of ATR to DSBs foci. Upon recruitment, 
ATR is subsequently activated by the DNA-protein structure, followed by the 
phosphorylation of its downstream target Chk1.  
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Understanding the convergence of ATM and ATR is taken one step further by showing 
that ATM is also activated in response to stimuli that are previously thought to activate 
ATR, such as UV and HU (Stiff, Walker et al. 2006). In addition, the activation of ATM is 
ATR-dependent without the requirement of γ-H2AX and 53BP1. ATM activation also 
leads to the phosphorylation and activation of its downstream target Chk2 to elicit 
cellular activities, such as cell cycle checkpoints.   
 Although the precise molecular events of ATM and ATR activation remain to be 
elucidated, growing evidence demonstrates a high degree of communication between 
these two kinases. ATM and ATR may function in an integrated molecular circuit to 
mediate diverse DNA damage signals and induce coordinated DNA damage response.  
1.4.3  DNA damage effect - cell cycle checkpoint control 
The survival of cells relies on faithful transmission of genetic information from parents to 
their progenies. This transmission requires not only accurate replication of DNA, but also 
the ability of cells surviving either spontaneous or induced DNA damage (Zhou and 
Elledge 2000). To preserve the stability of genome, cells have evolved the DNA damage 
repair and cell cycle checkpoint mechanisms to cope with DNA damage. These 
checkpoints verify whether the cellular activities at each phase of the cell cycle have been 
completed before cells progress to next phase. Three distinct checkpoints that have been 
identified and well studied are G1/S, intra-S and G2/M checkpoint.  
The G1/S checkpoint is at the end of G1 phase, making the decision of whether the cell 
should enter S phase or delay S phase. The intra-S phase checkpoint is activated when 
cells are exposed to DNA damage-inducing agents that interfere with ongoing DNA 
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replication. Activated intra-S phase checkpoint inhibits replication and delay cell cycle 
progression through S phase. And the G2/M checkpoint is at the end of G2 phase which 
check several criteria to ensure that the cell is ready for mitosis. If all the criteria are 
reached, the cell initiates many cellular processes for the beginning of mitosis (Lamarche, 
Orazio et al. 2010).  
 
Figure 1.3 Major pathways of ATM/ATR-mediated cell cycle arrest, including G1 arrest, 
intra-S arrest and G2 arrest. The regulatory role of Chk1 on intra-S arrest remains to be 
elucidated.  
 
ATM and ATR are the two protein kinases that phosphorylate numerous substrates to 
regulate cell cycle progression in response to DNA damage (Figure 1.3). The G1/S cell 
cycle checkpoint is mainly mediated by the activation and accumulation of p53 (Shiloh 
2001). p53 could be phosphorylated by ATM and ATR at many different sites, including 
Ser 6, 9, 15, 46 and threonine (Thr) 18 (Yang, Xu et al. 2004). In particular, Ser15 is the 
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common site that could be phosphorylated by both ATM and ATR, which is important for 
its transactivating activity (Shiloh 2001; Yang, Xu et al. 2004). Activated p53 turns on the 
transcription of one important gene, p21 (WAF1, Cip-1). p21 protein binds to several 
cyclin-Cdk complexes, which inhibits the complex activities and blocks cell cycle 
progression, resulting in G1 arrest (Levine 1997).  
The intra-S cell cycle checkpoint is also controlled by several branches of ATM-mediated 
signaling pathways (Kastan and Bartek 2004). One branch involves the phosphorylation 
of NBS1 by ATM, a process that is required for the following ATM-mediated 
phosphorylation of cohesin protein SMC1 that is implicated in the activation of intra-S 
checkpoint (Yazdi, Wang et al. 2002). Another branch involves the activation of Chk2 by 
ATM. Activated Chk2 phosphorylates the cell cycle regulator CDC25A, leading to the 
poly-ubiquitination-mediated degradation of CDC25A. CDC25A degradation will 
ultimately lead to the inhibition of cyclin E/A-CDK2 kinase complexes. Since new 
replication origin firing requires the activity of CDK2 kinase to recruit into pre-
replication complexes, inhibition of CDK2 kinase would finally block the DNA 
replication in S phase (Bartek, Lukas et al. 2004).  
Studies show that ATR is also implicated in intra-S checkpoint (Luciani, Oehlmann et al. 
2004). Slowing down the replication fork by DNA polymerase inhibitor aphidicolin 
strongly suppresses further initiation events and leads to intra-S cell cycle checkpoint. 
The intra-S checkpoint can be overcome by ATM/ATR kinase inhibitor, caffeine, or by 
ATR neutralizing antibodies, suggesting that the aphidicolin-induced checkpoint is ATR-
dependent (Luciani, Oehlmann et al. 2004). However, depletion or inhibition of Chk1 
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does not abolish the intra-S checkpoint, indicating Chk1 is not involved in the signaling 
pathway that induces this checkpoint (Luciani, Oehlmann et al. 2004). Other studies have 
raised controversial viewpoints regarding the role of Chk1 in inducing intra-S checkpoint 
by showing that Chk1 mediates the degradation of Cdc25A and leads to intra-S 
checkpoint (Xiao, Chen et al. 2003).  
In addition to regulating intra-S phase checkpoint, Chk2 is also known as a key regulator 
of the G2/M cell cycle checkpoint (Shiloh 2001). As a downstream target of ATM, Chk2 
could be phosphorylated at Thr68 by ATM when exposed to DNA damage-inducing 
agents that cause DSBs. In vitro, Chk2 phosphorylates the members of Cdc25 family, 
particularly Cdc25C at Ser216. The phosphorylation of Cdc25C creates a binding site for 
14-3-3 protein, leading to the formation of Cdc25C/14-3-3 complex, a process that 
sequesters Cdc25C in cytoplasm (Buscemi, Savio et al. 2001). The cytoplasmic Cdc25C 
fails to dephosphorylate and activate the cyclin-dependent nuclear kinase Cdc2, thus 
preventing mitosis and resulting in G2 arrest (Yang, Xu et al. 2004).  
Chk1 is also linked to G2 arrest in response to DNA damage in several cell types 
(Yamane, Taylor et al. 2004; Wang, Li et al. 2008). It has been shown that Chk1 is 
partially responsible for lithium-induced G2 arrest in hepatocellular carcinoma cells 
SMMC-7721. Using Chk1 inhibitor SB218078 or Chk1 siRNA, or overexpression of the 
kinase dead Chk1 abrogates the G2 arrest induced by lithium (Wang, Li et al. 2008). 
Moreover, using Chk1 siRNA also destroys the G2 arrest induced by chemotherapeutic 
drug 6-thioguanine in Hela cells (Yamane, Taylor et al. 2004). Chk1 is also revealed to 
mediate G2 arrest in glioma cells in response to temozolomide treatment (Hirose, 
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Katayama et al. 2004). These data collectively suggests that Chk1 is also actively 
involved in the regulation of G2/M checkpoint. 
1.4.4 DNA damage effect - apoptosis 
Following the induction of DNA damage, another prominent route of cellular activities is 
apoptosis. Apoptosis could be induced by many DNA damaging agents that cause 
collapse of replication forks and/or DSBs (Kaina and Roos 2006). If these lesions fail to 
be repaired, they will trigger the apoptosis signaling to eliminate unwanted cells through 
at least two pathways, the extrinsic pathway and the intrinsic pathway.  
Although rarely reported, ATM and ATR are also involved in mediating apoptosis 
signaling pathways by phosphorylating their downstream targets (Kaina and Roos 2006). 
p53 is the most extensively explored target that plays essential roles in modulating 
apoptosis. After activation, p53 regulates the apoptotic process primarily through intrinsic 
pathway that centers on mitochondria (Fridman and Lowe 2003).  
p53 controls the transcription of pro-apoptotic genes in the Bcl-2 family, such as Bax 
(BCL-2-associated X protein), Puma (p53 upregulated modulator of apoptosis), Noxa and 
Bid. The net effect of transcription is to increase the ratio of pro-apoptotic to anti-
apoptotic proteins, thereby favoring the release of apoptogenic factors from mitochondria, 
such as cytochrome c, AIF and SMAC/DIABLO (Kroemer and Reed 2000). The release 
of these factors from mitochondria to cytoplasm leads to the signaling cascade of 
caspases, the “executioner” of cell death, whereby promoting the occurrence of apoptosis 
(Kumar 2007). In addition to regulating the transcription of pro-apoptotic genes, p53 also 
activates the components that are involved in the apoptotic effector machinery, including 
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Apaf-1 and caspase 6, to potentiate cell death in the presence of cytochrome c (Fridman 
and Lowe 2003). 
Another ATM downstream target c-Abl is also implicated in eliciting apoptosis in 
response to IR (Shaul 2000). The phosphorylation of c-Abl by ATM induces the 
activation of p73, a family member of p53 that is also linked to apoptosis (Shiloh 2001). 
In cells that are null for c-Abl, the apoptotic response to IR is impaired (Yuan, Huang et 
al. 1997). Moreover, overexpression of c-Abl in combination of p73 is sufficient to 
induce apoptosis in fibroblasts (Agami, Blandino et al. 1999).  
1.4.5 DNA damage response as anti-cancer barrier 
Accumulating evidence suggests that cancer is essentially a disease of genes 
(Hoeijmakers 2001). The initiation and progression of cancer involves a series of DNA 
mutations that inactivate tumor-suppressor genes and activate proto-oncogenes. The 
observation that many tumor-suppressor genes that are inactivated during the process of 
carcinogenesis are components of the DNA damage response network (Bartek, Lukas et 
al. 2007) reflects the significance of the integrity of DNA damage response in preventing 
cancer. Recently, DNA damage response has been proposed as an anti-cancer barrier in 
early human carcinogenesis (Bartkova, Horejsi et al. 2005).  
ATM and ATR, as the central players in DNA damage response, serve as critical barriers 
to constrain tumor development. An investigation of the human tumor specimens from 
urinary bladder, lung, colon and breast shows phosphorylation of ATM, Chk2, p53, 
histone H2AX, as well as the 53BP1 foci (DiTullio, Mochan et al. 2002; Bartkova, 
Horejsi et al. 2005). Activation of ATM/ATR-mediated DNA damage pathways could 
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delay or prevent cancer in the early stage before malignant conversion. However, 
mutations in ATM/ATR signaling pathway might allow cell growth and limit cell death of 
the incipient cancer cells, thus increasing genomic instabilities and promoting tumor 
progression (Bartek, Lukas et al. 2007). Consistent with this viewpoint, mutation of TP53, 
the gene that encodes the tumor-suppressor protein p53, is found in 50% of human 
cancers (Toledo and Wahl 2006). Furthermore, the mouse model with targeted mutation 
of p53 (p53 S18, 23A) develops a wide spectrum of tumors after 1 year latency, suggesting 
the role of wild type p53 in tumor suppression (Chao, Herr et al. 2006).  
However, DNA damage response is not always activated in the early lesions of tumor. It 
has been reported that the activation of DNA damage response is observed in majority of 
human cancers, while not in testicular germ-cell tumors (Bartek, Lukas et al. 2007; 
Bartkova, Rajpert-De Meyts et al. 2007). This exception could be explained that the 
molecular events that drive the pathogenesis of testicular germ-cell tumors are unable to 
reach the threshold levels of DNA damage required for DNA damage response (Bartek, 
Lukas et al. 2007). The speculation may also provide some hints to the question of why 
the initial pre-malignant cells could grow and proliferate in the first place rather than 
being detected and eliminated by DNA damage response machinery. Another more likely 
explanation relies in the fact that not all oncogenic insults have the same ability to cause 
DNA damage, thus escaping from the surveillance of DNA damage response network. 
Examination of a variety of oncogenes shows that activation of the majority of oncogenes 
could evoke DNA damage responses, such as H-ras, c-Myc and E2F1 (Powers, Hong et 
al. 2004; Di Micco, Fumagalli et al. 2006; Pickering and Kowalik 2006; Reimann, 
Loddenkemper et al. 2007). However, a small subset of oncogenic events, such as 
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overexpression of proto-oncogene cyclin D1 and loss of tumor-suppressor gene p16ink4a, 
do not activate DNA damage responses (Bartek, Lukas et al. 2007).  
As a barrier of cancer development, DNA damage response on the other hand provides 
pressure that favors the growth of cells with defects in the DNA damage signaling 
machinery. Therefore, cells with deficient DNA damage signaling are preferentially 
selected to survive and perpetuate rather than being eliminated, which finally contributes 
to cancer initiation. Many human diseases caused by mutations of the genes involved in 
DNA damage signaling machinery have illustrated this point by showing a strong 
predisposition to cancer, such as A-T, NBS and ATLD (Metcalfe, Parkhill et al. 1996; 
Williams, Williams et al. 2007).   
Considering the importance of DNA damage signaling pathway in prevention of cancer 
development, it has become a target for cancer therapies. Conventional chemotherapy 
works by impairing the cell division of fast-proliferating cells, thus causing apoptosis. 
However, due to the potential mutations in DNA damage response machinery, cancer 
cells may favor cell cycle arrest rather than apoptosis, resulting in resistance to 
chemotherapeutic drugs. Therefore, choosing appropriate treatments to the cancer with 
specific cellular defects would have profound effects on outcome. Recent years, 
inhibitors of the proteins involved in DNA damage response pathway have been 
developed and used in a combination with other treatment strategies. For example, ATM 
inhibitors, KU55933 and CP466722, have been used to treat cancers and are effective in 
sensitizing cancer cells to IR (White, Choi et al. 2008). Chk1, the protein that is activated 
by ATR and induces intra-S and G2/M cell cycle arrest, is also a hot target in treating 
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cancers. Inhibitors of Chk1, such as UCN-01, XL844, PF-00477736 and AZD7762, are 
especially effective in cancer cells that are defective in G1/S cell cycle arrest (Ashwell 
and Zabludoff 2008; Ljungman 2009). Inhibitors that target other DNA damage signaling 
proteins, such as ATR, MRN complex, Chk2 and p53 have also been developed. They 
have been used to treat specific types of cancers to initiate cancer cell death rather than 




1.5 The biology of telomeres  
1.5.1 Telomere and telomerase 
Telomeres are highly specialized nucleoprotein structures at chromosome ends composed 
of telomeric DNA and associated proteins (Blackburn 2001). Telomeric DNA consists of 
a stretch of tandem G-rich repeats (5-26 bp) oriented 5’ to 3’ toward the chromosomal 
terminus (McEachern, Krauskopf et al. 2000). In humans, the telomeric repeat sequence 
is 5’-TTAGGG-3’ and the length of telomeric tract ranges from 5 to 15 kb which is kept 
in a cell-type specific manner (Lingner and Hug 2006). Due to the “end-replication” 
problem, the extreme end of telomeric DNA is a 3’ single-strand overhang rather than a 
duplex. In mammalian cells, the single-strand 3’-overhang of telomeric DNA folds back 
into the duplex telomeric DNA to form a “T-loop”, a process which protects eukaryotic 
chromosome ends from chromosome fusion, recombination and telomeric degradation 
(Blackburn 2001).  
The most common way to solve the “end-replication” problem occurs through telomerase, 
a specialized DNA polymerase that adds telomeric DNA repeats onto chromosome ends 
(Greider 1996). Telomerase is composed of two essential components, the protein 
component (TERT) and the RNA component (TER). The protein component contains the 
catalytic core of this enzyme, while the RNA component provides the template for 
telomeric DNA repeats (Blackburn 1992; Lingner and Hug 2006).  In human, the 
telomerase RNA has a length of 450 nucleotides which contains the redundant template 
nucleotides 5’-CUAACCCUAAC-3’. The redundancy of the RNA template allows the 
base pairing of RNA with growing telomere during replication (Greider 1996).  
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In addition to TERT and TER, the biogenesis and assembly of active telomerase requires 
additional protein subunits to mediate its access to telomeres (Cong, Wright et al. 2002). 
So far, at least 13 proteins that associate with human telomerase (hTERT and hTER) have 
been identified, including the molecular chaperone p23 and p90, the DNA damage 
response regulator 14-3-3, the H/ACA snoRNA (small nucleolar RNA) binding proteins 
dyskerin, hNOP10, hNHP2 and hGAR1, and hnRNPs (heterogeneous nuclear 
ribonucleoproteins) C1, C2, A1 and UP1. The telomerase-associated proteins are thought 
to regulate telomerase activity and modulate the accessibility of telomerase to telomeres. 
However, the precise actions of most telomerase-associated proteins are still unknown 
and remain to be determined (Cong, Wright et al. 2002).  
Telomerase-dependent telomere elongation occurs in S phase, while no elongation is 
observed in G1 phase of the cell cycle (Lingner and Hug 2006). The newly-synthesized 
telomeric DNA repeats will balance the loss of chromosome ends caused by the semi-
conservative DNA replication (Collins 2006). If the balance is lost, cells will suffer from 
cumulative loss of telomere repeats and eventually become senescence as a response to 
DNA damage when telomeres are critically short (de Lange 2005).  
However, telomerase is not a “housekeeping” enzyme that is found in all cell types. In 
most of human somatic cells, telomerase activity is distinguished during embryonic 
development, but only exists in several cell lineages, such as embryonic stem cells, germ 
cells, activated lymphocytes and almost all types of cancer cells (Shay and Bacchetti 
1997; Collins and Mitchell 2002). The loss of telomerase activity in human somatic cells 
has been suggested as an anti-cancer mechanism (Shay and Wright 2005). Reactivation of 
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telomerase activity exists in approximately 90% of all human cancers (Shay and 
Bacchetti 1997). Ectopic expression of hTERT in cooperation with other two oncogenes, 
the simian virus 40 large-T oncoprotein and an oncogenic allele of H-RAS, could 
successfully convert normal human epithelial and fibroblast cells into tumorigenic cells 
(Hahn, Counter et al. 1999).  
Telomerase activity is regulated at multiple levels, such as transcription, mRNA splicing, 
post-translational modification, transportation and localization, as well as assembly of 
active telomerase holoenzyme (Cong, Wright et al. 2002). But the regulation of hTERT 
gene transcription is the most important layer. In most situations, the hTERT expression 
level is the limiting factor and is closely correlated to telomerase activity in most cell 
types (Takakura, Kyo et al. 1999). Post-translational modification of hTERT, such as 
reversible phosphorylation, provides another important layer to control telomerase 
activity. Reversible phosphorylation of hTERT could regulate the protein structure and 
localization, thereby switching the active and inactive status of telomerase activity (Cong, 
Wright et al. 2002). 
The mechanisms that regulate telomerase activity are still not fully understood. 
Identification of new telomerase-associated proteins may contribute to the discovery of 
the unidentified cellular functions of telomerase. Revealing the multiple layers that 
regulate telomerase activity would further aid the investigation of the functions of 
telomerase in telomerase elongation, immortalization as well as carcinogenesis.  
1.5.2 Telomere and shelterin complex 
In mammalian cells, the telomeric TTAGGG repeats associate with shelterin complex 
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that is composed of six telomere-specific proteins, including telomeric repeat binding 
factor 1 (TRF1), TRF2, protection of telomeres 1 (POT1), the human ortholog of the 
yeast repressor/activator protein 1 (RAP1), the TRF1- and TRF2-interacting nuclear 
protein 2 (TIN2) and the POT1-TIN2 organizing protein 1 (TPP1) (de Lange 2005). The 
specificity of shelterin complex to telomere is determined by three of its components, 
TRF1, TRF2 and POT1 (Palm and de Lange 2008). TRF1 and TRF2 directly bind to the 
duplex region of telomeres, whereas POT1 binds to the single-strand 3’-overhang. These 
three proteins are interconnected by the rest three components of shelterin, RAP1, TIN2 
and TPP1, and form a stable complex binding to telomeres (de Lange 2005; Palm and de 
Lange 2008).  
Shelterin complex is implicated in the protection of telomeres by affecting the structure 
of telomeres. The natural ends of telomeres are long single-strand 3’-overhangs. However, 
electron microscopy of the purified telomeric restriction fragments stabilized by psoralen 
and UV in both human and mouse cells showed that telomeres are presented as “T-loops” 
(Griffith, Comeau et al. 1999). Accumulating evidence suggests that the shelterin 
complex has DNA remodeling activities that are responsible for “T-loop” formation (de 
Lange 2005). At least three components of the shelterin complex have been identified 
with DNA remodeling activity, including TRF1, TRF2 and TIN2. TRF2 can remodel 
artificial telomeres into loops, although with low efficiency (Griffith, Comeau et al. 1999). 
TRF1, with the help of TIN2, can bend and pair telomeric DNA repeats in vitro, activities 
which might correspond to the folding of telomeres into “T-loops” in vivo (Bianchi, 
Smith et al. 1997).  
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By hiding into “T-loops”, telomeres are protected from being recognized as DSBs by 
DNA damage signaling machinery. Inhibition or loss of shelterin complex components 
would therefore jeopardize the integrity of telomeres and lead to DNA damage response 
at telomeric ends. Recent studies revealed that the canonical DNA damage signaling 
pathways are involved in protecting telomere integrity, particularly the ATM- and ATR-
mediated pathways (de Lange 2005). It was firstly found that inhibition of TRF2 with a 
dominant negative version activates ATM kinase as well as its downstream target p53, 
and leads to p21-mediated G1/S cell cycle arrest (Karlseder, Broccoli et al. 1999). The 
mouse model with conditional deletion of TRF2 confirms this result by showing 
accumulated telomere dysfunction induced foci (TIFs) formed by 53BP1, γH2AX and 
phosphorylated ATM (Celli and de Lange 2005). In contrast to TRF2, depletion of POT1 
activates ATR signaling pathway and ATR-dependent phosphorylation of Chk1. When 
inhibition of ATR by shRNA, the telomere damage response is significantly suppressed 
indicated by a pronounced decrease of TIFs (Denchi and de Lange 2007). Conditional 
deletion of TRF1 activates both ATM and ATR kinases and their substrates Chk1 and 
Chk2. Inhibition of kinase activities by ATM and ATR inhibitors rescues TIFs induced by 
TRF1 deletion, which further manifests the involvement of both ATM and ATR pathways 
in response to dysfunctional telomeres (Martinez, Thanasoula et al. 2009). TIFs 
formation has also been reported when TIN2 is inhibited (Kim, Beausejour et al. 2004). 
Collectively, these data argue the importance of shelterin complex components in 
protecting telomere integrity and repressing the DNA damage responses at telomeric ends.  
As a consequence of telomere dysfunction, telomeric fusions are frequently observed in 
cells deprived of protection from shelterin complex. One type of telomeric fusions is non-
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homologous end joining (NHEJ) which involves covalent fusions of the C-strand of one 
telomere and the G-strand of another thus creating a dicentric or circular chromosome 
(Smogorzewska, Karlseder et al. 2002). Inhibition or loss of shelterin components, such 
as TRF1, TRF2, POT1 and TPP1, leads to accumulated NHEJ in cells (de Lange 2005; 
Denchi and de Lange 2007; Martinez and Blasco 2010). Another type of telomeric 
fusions is homologous recombination (HR) in which DNA sequences are exchanged 
between similar or identical fragments. HR has been observed in cells with functional 
mutation of TRF2, named TRF2ΔB. TRF2ΔB mutants are protected from NHEJ but show 
telomere truncations and contain circular extrachromosomal telomeric DNA (Cesare and 
Griffith 2004). HR between telomeres could result in generation of aberrant telomere 
length and lead to telomere deletions, inversions as well as translocations which are 
detrimental to cells (de Lange 2005). Thus, shelterin complex components play essential 
roles in preventing telomeric fusion-associated cell death.  
Shelterin complex components are negative regulators of telomere length. Long-term 
overexpression of TRF1 leads to gradual telomere shortening without affecting the 
expression of telomerase in human sarcoma cell line HT1080 (vanSteensel and deLange 
1997). Mouse model with transgenic TRF1 expression in the context of epithelial tissues 
(K5TRF1 mouse) has shorter telomeres in the epidermis compared to wild-type control. 
Moreover, K5TRF1 cells exhibit increased aberrant telomeric fusions, such as end-to-end 
fusions, telomere recombination and multitelomeric signals (Munoz, Blanco et al. 2009). 
Similar to TRF1, overexpression of TRF2 is also implicated in negative regulation of 
telomere length in both mouse and human cells (Smogorzewska, Van Steensel et al. 2000; 
Munoz, Blanco et al. 2005). The same effect of negative regulation of telomere length has 
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also been reported in cells with TIN2 or RAP1 overexpression (Kim, Beausejour et al. 
2004; O'Connor, Safari et al. 2004). However, how shelterin components exert the 
negative effect in regulation of telomere length is far from being fully understood.  
1.5.3 Other telomere associated proteins  
In addition to shelterin complex, telomeres also bind to a large number of other proteins 
that are involved in DNA damage signaling and repair pathways (Table 2) (Munoz, 
Blanco et al. 2006). In particular, these proteins include MRN complex, Ku70/80 and 
ATM (Munoz, Blanco et al. 2006; Palm and de Lange 2008). Unlike shelterin complex, 
these proteins have non-telomeric functions and are typically more abundant at non-
telomeric sites in nucleus or cytoplasm (Palm and de Lange 2008). The association of 
these proteins to telomeres suggests a role in protecting and maintaining telomere 
integrity. Ku70/80, the protein involved in NHEJ, is required for telomere localization to 
the nuclear periphery (Galy, Olivo-Marin et al. 2000), while loss of Ku70/80 function 
leads to striking recombinational activities near chromosomal ends (Baumann and Cech 
2000). RAD50, MRE11and XRS2 (the ortholog of NBS1 in yeast) have also been 
implicated in the maintenance of telomeres. Mutation of any of these genes leads to 
pronounced telomere shortening in S. cerevisiae (Le, Moore et al. 1999). The role of 
ATM at telomeric ends is manifested by A-T disease in human that ATM gene mutation 





Table 2. List of non-shelterin proteins associated with telomeres 
Protein  Telomeric 
interaction 




MRN TRF2 Telomere length 
regulation; prevent 
telomeric end fusions 









DSB response Mutations cause 
cancer onset 

























Rad9 is abundant 
in prostate 
cancer 




















from DNA repair 
5’ exonuclease NK 
PINX1 TRF1/ 
TERT 




Tankyrase TRF1 Telomere length 
regulation 
Role in mitosis Overexpressed in 
many cancers 





RAD51D NK Prevention of 
telomeric fusions 
HR repair Mutations cause 
cancer onset 
ORC1 TRF2 NK Replication 
initiation 
NK 
‘NK’ means not known. Abbreviations: NER: nucleotide excision repair; BER: base excision 
repair; WRN: gene mutated in Werner syndrome; BLM: gene mutated in Bloom syndrome; 
PINX1: PIN1-interacting protein 1; PARP: poly-ADP-ribose-polymerase; ORC1: origin 
recognition complex subunit 1. Selected references: MRN (Lamarche, Orazio et al. 2010); ATM 
(Pandita 2002); WRN (Li, Jog et al. 2008); BLM (Lillard-Wetherell, Machwe et al. 2004); DNA-
PKcs, Tankyrases, PARP1/2, RAD51D (de Lange 2005); Ku70/80 (Ponnusamy, Alderson et al. 
2008); XPF/ERCC1 (Wu, Mitchell et al. 2008), ORC1 (Noguchi, Vassilev et al. 2006).  
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Direct interaction between shelterin components, especially TRF2, and factors that are 
involved in DNA damage response has been observed. TRF2 serves as a protein hub at 
telomeric ends and interacts with a number of factors, such as MRN complex and ATM 
(Munoz, Blanco et al. 2006). The interaction indicates an interplay between DNA damage 
response and telomere integrity maintenance. Indeed, canonical DNA damage responses 
are activated when telomeres are deprived of protection from shelterin components (as 
discussed above in section 1.5.2). In turn, shelterin components might also influence 
DNA damage response. It has been observed that overexpression of TRF2 inhibits ATM 
autophosphorylation at Ser1981 as well as the phosphorylation of its downstream targets, 
NBS1 and p53, after IR (Karlseder, Hoke et al. 2004).  
1.5.4 Telomerase and shelterin in cancer and aging 
In most normal human somatic cells, the low telomerase level is insufficient to maintain 
telomere length and support indefinite cell division. Therefore, these cells undergo 
gradual telomere attrition with age which eventually results in critically short telomeres 
and senescence, indicating a direct link between telomere length and cellular aging 
(Harley, Futcher et al. 1990). In many diseases that are associated with premature aging, 
short telomeres are observed, such as A-T, NBS, Werner syndrome and Bloom syndrome 
(Munoz, Blanco et al. 2006). In addition, short telomeres are also observed in late stage 
cancers, probably due to their long proliferation history (Blasco 2005).  
Reactivation of telomerase is observed in more than 90% of human cancers (Shay and 
Bacchetti 1997), indicating that acquisition of telomerase is one of the essential steps in 
tumorigenesis. Some cancers that are not detectable of telomerase activity maintain 
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telomere length by another telomerase-independent mechanism, alternative lengthening 
of telomeres (ALT) (Henson, Neumann et al. 2002). Although with telomere lengthening 
mechanisms, tumors generally have shorter telomere length than their surrounding 
normal tissues which may eventually lead to cell death within tumors (Blasco 2005).  
The impact of short telomeres in the whole organism has been manifested by telomerase-
deficient mouse model. The first telomerase deficient mouse was generated by deletion of 
the mouse TER component (mTER) from germline. The mTER-/- mice are only viable for 
six months and suffer from a series of pathologies associated with loss of telomeric DNA 
repeats, including a reduction in proliferation potential, increased apoptosis, loss of 
fertility, decreased tissue regeneration and tissue atrophies (Blasco, Lee et al. 1997; 
Blasco 2005). Reintroduction of mTER gene into the mTER-/- mice prevents telomere 
shortening, premature aging and loss of organismal viability (Samper, Flores et al. 2001). 
These results suggest that an appropriate telomere length is necessary to maintain tissue 
homeostasis.  
Recent studies show that shelterin components also play a role in cancer susceptibility 
even in the presence of normal telomerase activity. Aberrant expression of TRF1, TRF2, 
TIN2 and POT1 is observed in some human tumor types (Blasco 2005; Martinez and 
Blasco 2010). To study the function of shelterin components in cancer and aging, mouse 
models with genetic modification of various shelterin components have been generated. 
However, complete deletion of TRF1, TRF2, POT1a, TPP1 or TIN2 leads to early 
embryonic lethality (Martinez and Blasco 2010). Due to this fact, tissue specific 
conditional mouse models and transgenic mouse models have been generated recently to 
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study the potential roles of shelterin components in caner and aging (Martinez and Blasco 
2010).  
Conditional deletion of TRF1 in stratified epithelia (TRF1Δ/Δ K5-Cre mice) leads to 
perinatal death and multiple skin abnormalities, such as skin hyperpigmentation, skin 
morphogenesis and absence of mature hair follicles (Martinez, Thanasoula et al. 2009). 
p53 deletion in TRF1Δ/Δ K5-Cre mice rescues mice survival and most of the skin-related 
defects, indicating that the defects associated with TRF1 deletion are mediated by p53. 
TRF1/p53 double null mice develop squamous cell carcinomas, suggesting a tumor 
suppressive effect of TRF1 (Martinez, Thanasoula et al. 2009). TPP1Δ/Δ K5-Cre mice 
show similar phenotypes as that observed in TRF1Δ/Δ K5-Cre mice (Tejera, d'Alcontres et 
al. 2010). As an ortholog of TRF1, TRF2 is also implicated in tumorigenesis. TRF2 
transgenic mice (K5TRF2 mice) exhibit severe skin defects and an increased incidence of 
skin cancer (Munoz, Blanco et al. 2005). In line with this, an elevation of TRF2 is 
frequently observed in human skin carcinomas (Munoz, Blanco et al. 2005). However, 
conditional deletion of TRF2 in liver does not compromise mice viability and liver 
regeneration, probably due to the fact that liver regeneration occurs without cell division, 
thus circumventing the chromosome segregation problems caused by TRF2 deletion 
(Denchi, Celli et al. 2006).   
Mouse contains two POT1 orthologs, POT1a and POT1b. POT1a and POT1b have 
different roles revealed by single knockouts. While abrogation of POT1a results in 
embryonic lethality, POT1b-deficient mice survive to adulthood and show degenerative 
abnormalities, such as skin hyperpigmentation and bone marrow failure (Hockemeyer, 
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Daniels et al. 2006). Because of the embryonic lethality of TIN2 knockout mice, 
conditional or tissue-specific TIN2 knockout mice are required for further analysis of its 
in vivo function. RAP1 deficiency mouse models suggest that RAP1 is not required for 
viability but important in protection of telomeres from recombination (Sfeir, Kabir et al. 
2010).   
Understanding the roles of telomerase and shelterin complex in human diseases is 
essential for designing appropriate therapeutic strategies. In diseases associated with 
premature aging and shortened telomeres, reactivation of telomerase is one of the 
potential strategies. It has been reported that the telomere-elongation defect of NBS could 
be rescued by simultaneous reintroduction of NBS1 and hTERT (Ranganathan, Heine et al. 
2001). In cancers characterized by high telomerase activity, anti-telomerase is an 
important aspect for cancer therapy. However, targeting telomerase is challenging due to 
the lag period that anti-telomerase inhibitor takes to exert cytotoxic effects 
(Satyanarayana, Manns et al. 2004). The most likely use of anti-telomerase inhibitors is 
as an adjuvant strategy in combination with surgery (Shay, Zou et al. 2001). In addition, 
the fact that expression of shelterin components TRF1, TRF2 and TIN2 is altered in 
human cancers raises the potential of using them as therapeutic targets for cancer. Future 
investigation of the biology of shelterin components in diseases and cancers would 




1.6 Project rationale and aims 
Accumulating evidence suggests that NBS1 is involved in both ATM- and ATR-
dependent signaling pathways. In addition to being a downstream substrate that could be 
phosphorylated by either ATM or ATR in response to specific type of DNA lesions, NBS1 
is also reported as an upstream regulator of ATM that influences ATM 
autophosphorylation. However, whether NBS1 is also an upstream regulator of ATR is 
not fully understood.  
The involvement of NBS1 in cell cycle checkpoint is reported in several studies. In 
response to IR, NBS cells failed to induce intra-S checkpoint control (Tauchi, Matsuura 
et al. 2002). Defects in inducing G1/S and G2/M checkpoint have also been observed in 
NBS cells (Buscemi, Savio et al. 2001). However, other studies showed normal and 
proficient G1/S and G2/M checkpoint in spite of NBS1 deficiency (Antoccia, di Masi et 
al. 2002). The role of NBS1 in maintaining checkpoint integrity still remains 
controversial. Moreover, the influence of NBS1 deficiency in apoptosis is rarely reported 
and how NBS1 regulates DNA damage induced apoptosis is waiting to be elucidated.  
Besides cell cycle checkpoint and apoptosis, NBS1 also plays a role in telomere 
maintenance (Lamarche, Orazio et al. 2010). In yeast, XRS2, the functional homolog of 
NBS1, is involved in telomerase-dependent telomere synthesis (Wu, Xiao et al. 2007). In 
human, NBS1 is associated with shelterin component TRF2 in S phase while not in other 
phases (Zhu, Kuster et al. 2000). The interaction of NBS1 and TRF2 in S phase suggests 
a role of NBS1 in telomere replication. Furthermore, it has been reported that NBS 
fibroblasts showed premature growth cessation in culture. But the mechanism of how 
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NBS1 deficiency affects telomere replication and attrition, therefore premature aging is 
far from fully established.   
This study aims to examine the roles of NBS1 both in DNA damage signaling pathway 
and in maintaining telomere integrity. On one hand, the role of NBS1 as an upstream 
regulator of both ATM and ATR will be examined by using NBS cells derived from NBS 
patients with 657del5 mutation. The function of NBS1 in regulating DNA synthesis and 
apoptosis will also be examined after introduction of DNA damage by Dox treatment. On 
the other hand, the telomere shortening rate of NBS cells will be determined in vitro and 
compared with the age, gender and race-matched normal counterparts. If aberrant 
telomere shortening rate is observed in NBS cells, this study will further elucidate the 
underlying mechanism of how NBS1 affects the telomere shortening rate by looking into 
the potential changes in telomerase activity and shelterin complex in NBS cells.  
Cancer predisposition is one of the characteristics of NBS disease. As telomere 
dysfunction has been implicated in carcinogenesis, this study will also examine the 
integrity of telomeres in NBS cells. If frequent telomere aberrations are observed in NBS 
cells, this study would provide new evidence to explain the high incidence of cancers in 





2. MATERIALS AND METHODS 
2.1 Cells  
Table 3. List of fibroblasts and B-lymphocytes used in this study 
 
 
Disease Cat. ID Cell type Immort-
alization 
Age Sex race 
Pair1 Normal AG09309 Fibroblast NA 21 F Caucasian 
NBS GM07166 Fibroblast NA 20 F Caucasian 
Pair2 Normal GM00637 Fibroblast SV40 18 F Caucasian 
NBS GM15989 Fibroblast SV40 20 F Caucasian 
Pair3 Normal AG14725 B-lymphocyte EBV 11 M Caucasian 
NBS GM15814 B-lymphocyte EBV 12 M Caucasian 
Pair4 Normal GM22671 B-lymphocyte EBV 28 F Caucasian 
NBS GM07078 B-lymphocyte EBV 20 F Caucasian 
Normal 
fibroblast 
GM01864 Fibroblast NA 11 M Caucasian 







Table 4. List of cancer cells used in this study 
 
Disease Cat. ID Cell type Origin  
Breast cancer MCF7 HTB-22 Epithelial mammary gland 
Colon cancer HCT116 CCL-247 Epithelial colon 
 
Cells used in this study were obtained from Coriell Cell Repositories (CCR) or  ATCC. In 
each pair, the NBS cells were paired with normal cells under the criteria of age, gender 
and race. The NBS cell lines within each pair are homozygous for a deletion of 5 
nucleotides in exon 6 of NBS1 gene, called 657del5 mutation. Additionally, another three 
cell lines, including one normal fibroblast cell line GM01864, the human breast cancer 
cell line MCF7 and the human colon cancer cell line HCT116 were also used in particular 
experiments.  
Fibroblast cell lines at CCR were established by outgrowth of undifferentiated 
mesodermal cells from a biopsy. The morphology of fibroblasts is spindle shaped or 
stellate. B-lymphocytes were isolated as peripheral blood mononuclear cells and 
transformed with Epstein-Barr virus. The B-lymphocytes are small round cells that grow 




2.2 Cell culture 
2.2.1 Cell culture conditions 
The five fibroblast cell lines were cultured in Minimum Essential Medium Eagle (MEM, 
Gibco, Invitrogen) and the four B-lymphocytes cell lines were cultured in Roswell Park 
Memorial Institute-1640 (RPMI-1640, Sigma-Aldrich). Both medium was supplemented 
with 15% fetal bovine serum (FBS, Gibco, Invitrogen), 1% L-Glutamine (Gibco, 
Invitrogen), 1% non-essential amino acid (NEAA, Gibco, Invitrogen) and 1% vitamin 
solution (Gibco, Invitrogen), 100 U/ml penicillin and streptomycin (Gibco, Invitrogen) 
and incubated in 37 °C under 5% CO2. The two cancer cell lines were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco, Invitrogen) supplemented with 
10% heat-inactivated FBS, 1% L-Glutamine and 100 U/ml penicillin and streptomycin.  
2.2.2 Cell harvesting 
Fibroblasts and cancer cells were harvested by trypsinization. Growing medium was 
removed and cells were washed with PBS once. 0.25% (w/v) Trypsin with 0.38 g/L 
EDTA (Gibco, Invitrogen) was added into cell culture dish which was then incubated in 5% 
CO2, 37 oC incubator for 3 minutes. Cells were resuspended with MEM (for fibroblasts) 
or DMEM (for cancer cells) and centrifuge at 1000 × g for 5 minutes. The medium was 
aspirated and the pellet was washed with PBS twice. Cells were then used for following 
experiments.   
B-lymphocytes were harvested in tubes and centrifuge at 1000 × g for 5 minutes. The 
medium was aspirated and the pellet was washed with PBS twice. Cells were then used 
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for following experiments.  
2.2.3 Cell storage 
For storage of cells, the pellet was resuspended with freezing medium composed of 10% 
DMSO (Sigma-Aldrich) and 90% FBS, and stored in cryovials (Thermo Scientific). 




2.3 Western Blotting  
2.3.1 Protein extraction and separation 
Cell pellet was resuspended in 50 mmol/L Tris-HCl (pH 7.4), 250 mmol/L NaCl, 5 
mmol/L EDTA, and 0.1% NP-40 with protease and phosphatase inhibitors (1 µg/ml 
Aprotinin, Leupeptin and Pepstatin, 1 mM NaF, 1 mM Na3VO4 and 1 mM PMSF). The 
lysate were centrifuged at 17,000 × g for 10 minutes before protein quantitation using 
Bradford assay (Biorad). The lysates were then mixed with reducing agent, 5 × loading 
buffer with 20 × DTT (Fermentas), and boiled at 95 oC for 5 minutes. The protein was 
run on appropriate SDS-PAGE gels and transferred to nitrocellulose membrane 
(Millipore). After transfer, the membrane was incubated with 5% skimmed milk, primary 
antibody and secondary antibody sequentially. Following incubation, the membrane was 
washed using Tris buffered saline- 0.1% (v/v) Tween 20 (TBST). Horseradish peroxidase 
(HRP) conjugated secondary anti-mouse or anti-rabbit IgG antibodies were used. 
Immunostaining was detected using ECL Plus Detection Regent (GE healthcare).  
2.3.2 Antibodies  
Table 5. List of antibodies used in this study 
 




NBS1 Cell signaling #3002 Rabbit  95 
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ATM Novus Biologicals NB100-104 Rabbit  370 
ATM-pS1981 Rockland #200-301-400 Mouse  370 
ATR Cell signaling #2790 Rabbit  250 
ATR-pS428 Cell signaling #2853 Rabbit  300 
Chk2 Cell signaling #2662 Rabbit  62 
Chk2-pT68 Cell signaling #2661 Rabbit  62 
Chk1 Cell signaling #2345 Rabbit  56 
Chk1-pS317 Cell signaling #2349 Rabbit 56 
p53 Cell signaling #9286 Mouse  53 
p53-pS15 Cell signaling #9284 Rabbit  53 
γH2AX-pS146 Novus Biologicals NBP1-19255 Mouse  14 
p21 Cell signaling #2946 Mouse  21 
Cleaved caspases 3 Cell signaling #9664 Rabbit  17,19 
PARP Abcam  #9542 Rabbit  24, 116 
TRF1 Abcam  Ab14397 Mouse  55 
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POT1 Abcam  Ab47082 Rabbit  71 
RAP1 Bethyl laboratories A300-306A Rabbit  60 
TIN2 Abcam Ab13791 Mouse 39 
TPP1 Abnova H00065057-M02 Mouse 86 
TOPBP1 Calbiochem PC743 Rabbit  180 
α-tubulin Sigma-Aldrich T9026 Mouse  50 
HRP-GAPDH Cell signaling #3683 Rabbit  37 




2.4 5-Bromo-2’-deoxy-uridine (BrdU) Labeling & Detection (Roche, Cat. No. 
11444611001) 
Cells were cultured in 96-well flat bottom plates (Thermo Scientific) in a density of 
10,000 cells per well and incubate for 24 hours. 10 µM BrdU labeling solution and 1 µM 
Dox were added to culture medium at the same time and cells were incubated for either 
10 hours or 22 hours. Before removing the culture medium, suspension cells were spin 
down for 10 minutes at 300 × g in a centrifuge. Cells were dried to the bottom of the 96-
well plate for approximately 2 hours at 60 oC. Then, cells were fixed with 200 µl 
precooled fixative (70% ethanol p.a. in 0.5 M HCl) per well for 30 minutes at -30 oC. 
Fixative was removed and cells were washed 3 times with 250 µl wash medium (PBS 
containing 10% FBS) per well. Cells were Incubated with 100 µl nuclease working 
solution per well for 30 minutes at 37 oC water bath. Nuclease working solution was 
removed and cells were washed 3 times with 250 µl wash medium containing 10% FBS 
per well. 100 µl anti-BrdU-POD, Fab fragments, working solution was added per well for 
30 minutes at 37 oC. Cells were washed 3 times with 250 µl washing buffer after 
antibody conjugate was removed. 100 µl peroxidase substrate was added per well. Cells 
were incubated at room temperature until positive samples show a green color, and is 
clearly distinguishable from the color of pure peroxidase substrate (2-30 minutes). 
Extinction of the samples was measured in a microplate reader at 405 nm with a 
reference wave-length at approximately 490 nm.   
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2.5 FITC Annexin V Apoptosis Detection (BD Pharmingen, Cat. No. 556570)  
Cells were seeded with a density of 1 × 105 cells/ml in 10 ml medium, 1 day prior Dox 
treatment. Dox concentration and incubation period was decided based on experimental 
design. Cells were collected by centrifugation  at 500 × g for 5 minutes. Cells were 
washed 2 times with cold PBS and resuspended in 1 × Binding Buffer at a concentration 
of 1 × 106 cells/ml. 100 µl of the solution (1 × 105 cells) was transferred to a 5 ml culture 
tube containing 5 µl of FITC Annexin V and 5 µl propidium iodide (PI). Cells were 
incubatesd for 15 minutes at room temperature in the dark. After incubation, 400 µl of 1 
× Binding Buffer was added to each tube. Just before doing flow cytometry, cells were 
transferred to the flow tube through the filter (60 µm). Samples were analyzed within 1 




2.6 TeloTAGGG Teloere Length Assay (Roche, Cat. No. 12209136001) 
Genomic DNA was extracted using DNeasy Blood & Tissue Kit (Qiagen). Cells 
(maximum 5 × 106) were centrifuged for 5 minutes at 300 × g. Pellet was resuspended in 
200 µl PBS and with 20 µl proteinase K. Subsequently, 200 µl Buffer AL was added 
(without added ethanol) into the cell mixture. Mixture was mixed thoroughly by 
vortexing 5-10 seconds and incubated at 56 oC for 10 minutes. After incubation, 200 µl 
ethanol (96-100%) was added to the sample and thoroughly mixed by vortexing. The 
mixture was transferred into the DNeasy Mini spin column placed in a 2 ml collection 
tube and centrifuged for 1 minute at 6,000 × g. After centrifugation, flow-through and the 
collection tube were discarded. DNeasy Mini spin column was replaced in a new 
collection tube. 500 µl Buffer AW1 was added before centrifugation for 1 minute at 6,000 
× g. Flow-through and collection tube were discared again. DNeasy Mini spin column 
was replaced in a new collection tube. 500 µl Buffer AW2 was added before 
centrifugation for 3 minutes at 20,000 × g to dry the DNeasy membrane. Flow-through 
and collection tube were discared and  the DNeasy Mini spin column was placed in a 
clean 1.5 ml microcentrifuge tube. 30-50 µl Buffer AE was added directly onto the 
DNeasy membrane. Column was incubated at room temperature for 1 minute, then 
centrifuged for 1 minute at 6,000 × g to elute. DNA concentration was determined using 
Nanodrop (Thermo Scientific). The extracted genomic DNA was stored at -80 oC freezer.  
Genomic DNA (1-2 µg) was digested by enzyme Hinf I and Rsa I for 2 hours at 37 oC. To 
stop the reaction, 5 μl of gel electrophoresis loading buffer was added with quick-spin of 
the reaction vial. Separation of digested DNA was done by 0.8% agarose gel 
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electrophoresis at 5 V/cm in 1 × TAE buffer until the bromophenol blue tracking dye is 
separated about 10 cm from the starting well. Gel was submerged in HCl solution and 
agitated for 5-10 minutes at room temperature, until the bromophenol blue stain changes 
color to yellow. Gel was rinsed 2 times with water before submerged in the denaturation 
solution and neutralization solution sequentially for 2 × 15 minutes. Gel was rinsed 2 
times with water after each submergence. Digested DNA was blotted from the gel to 
nylon membrane by capillary transfer using 20 × SSC as a transfer buffer overnight. After 
southern transfer, transferred DNA on the wet blotting membrane was fixed by UV-
crosslinking (120 mJ). Membrane was washed 2 times with 2 × SSC. For 
prehybridization, blot was submerged in prewarmed DIG Easy Hyb and incubated for 30-
60 minutes at 42 oC. Prehybridization solution was discarded and hybridization solution 
was added to the membrane immediately. Membrane was incubated for 3 hours at 42 oC 
before washed twice with stringent wash buffer I for 5 minutes, followed by wash with 
stringent buffer II for 15-20 minutes at 50 oC.  Membrane was rinsed in 100 ml 1 × 
washing buffer for 1-5 minutes. Then membrane was incubated in 100 ml freshly 
prepared 1 × blocking solution for 30 minutes. After blocking, membrane was incubated 
in 500-100 ml Anti-DIG-AP working solution for 30 minutes. Membrane was washed 
twice with 1 × washing buffer for 15 minutes before incubated in 100 ml of 1 × detection 
buffer for 2-5 minutes. Detection buffer was discarded and excess liquid was removed 
from the membrane by placing the membrane, DNA side up, on a sheet of absorbent 
paper. Wet membrane was immediately placed, DNA side facing up, on an opened 
hybridization bag and approximately 40 drops substrate solution was very quickly 
applied to the membrane. Substrate solution was carefully spread homogeneously over 
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the membrane without trapping air bubbles. Membrane was incubated for 5 minutes 





2.7 β-galactosidase Staining (US Biological, Cat. No. G1041-76) 
Normal and NBS fibroblasts were cultured to the population doubling level (PDL) as 
required. PDL = 3.32(log (total viable cells at harvest/total viable cells at seed)). Growth 
medium was removed from the cells. The plate was rinsed 1 time with PBS. 1 ml of 1 × 
Fixative Solution was added to each 35 mm well to fix cells for 10-15 minutes at room 
temperature. The plate was rinsed two  times with  PBS.  1  ml o f th e β-galactosidase 
staining solution was added and the plate was incubated at 37 oC overnight in incubator. 
The next day, while the staining solution is still on the plate, the cells were checked under 




2.8 Growth curve study 
NBS as well as normal B-lymphocytes were cultured and split 1:3 every other day. Cell 
number was counted every time when splitting. Cells were seeded for growth in flasks 
(Thermo Scientific) with a density of 1 × 105 cells/ml medium. Cells were cultured for 18 






2.9 Telomerase activity assay (XpressBio, Cat. No. XT-100) 
Count cells and take 1 × 106 cells to use. Spin down cells and wash with PBS for 2 times. 
Resuspend cell pellet in 50 µl TeloExpress Lysis Buffer and incubate on ice for 30 
minutes. Spin the sample at 12,000 × g for 3 minutes at 4 oC. Transfer supernatant to a 
fresh microcentrifuge tube. Respin sample at 12,000 × g for 20 minutes at 4 oC. Transfer 
supernatant to another fresh microcentrifuge tube. Then quantify protein concentration by 
Bradford assay. Dilute sample to a final concentration of 1.1 µg/µl with TeloExpress 
Lysis Buffer (5 µl in total). Add 1 µl sample into PCR Reaction Mixture (15 µl 
TeloExpress Master Mix and 9 µl RNase-free Water for one reaction) and mix well in 
PCR tubes. Place the tubes in the real-time PCR instrument (Qiagen, Rotor-Gene Q) and 
start the program. Use the real-time PCR instrument’s software to plot threshold cycle 





Total RNA was extracted using RNeasy kit with on-column DNase digestion (Qiagen) 
with slight modifications. Cell pellet was washed with PBS twice before Trizol 
(Invitrogen) lysis of samples. Pipet up and down for at least six times before 
centrifugation at 12,000 × g for 10 minutes at 4 oC. After centrifugation, transfer the 
supernatant into a new 1.5 ml microcentrifuge tube and add appropriate amount of 
chloroform to each tube (trizol : chloroform = 5:1). Shake by hands for 15 seconds before 
incubation for 2-3 minutes at room temperature. Centrifuge at 12,000 × g for 15 minutes 
at 4 oC to separate different layers. Transfer the upper colorless layer into a new 1.5 ml 
microcentrifuge tube. Add 1 volume of 70% ethanol to the colorless lysate and mix well 
by pipetting. Transfer up to 700 µl of the sample to an RNeasy spin column placed in a 2 
ml collection tube and centrifuge for 15 seconds at 8,000 × g. Discard the flow-through 
and add 350 µl Buffer RW1 to the column and centrifuge for 15 seconds at 8,000 × g. 
Discard the flow-through, add 80 µl DNase I incubation mixture directly to the column 
membrane and place on bench top for 15 minutes. Then add 350 µl Buffer RW1 to the 
RNeasy spin column and centrifuge for 15 seconds at 8,000 × g. Add 500 µl Buffer RPE 
to the column after discarding flow-through and centrifuge at 8,000 × g for 15 seconds. 
The same step was repeated with centrifugation for 2 minutes. Place the RNeasy spin 
column in a new 1.5 ml microcentrifuge tube and add 30-50 µl RNase-free water directly 
onto the column membrane. Incubate at room temperature for 1 minute and centrifuge at 
8,000 × g for another 1 minute to elute. Determine the total RNA concentration using 
Nanodrop. The extracted mRNA was stored at -80 oC freezer.  
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One step RT-PCR was performed using the One Step RT-PCR kit (Qiagen) following 
manufacturer’s protocol. mRNA was transcribed and amplified following the program as 
described using Thermal Cyclers PCR machine: DNA synthesis for 30 minutes at 50 oC, 
followed by initial PCR activation step for 15 minutes at 95 oC. The three-step cycling 
profile is as follows: Denaturation at 94 oC for 30 seconds, Annealing at 55 oC for 30 
seconds and Extension at 72 oC for 1 minute for 30 cycles. Final extension is at 72 oC for 
10 minutes, followed by 4 oC forever. The primers for TRF2 are: 5’-TGCTCAAGTTCTA 
CTTCCACGA-3’ and 5’-TTGATAGCTGATTCCAGTGGTG-3’. PCR products were run 




2.11 Cytogenetic analysis of metaphase spreads 
Normal and NBS fibroblasts were cultured to late passages. Metaphase spreads were 
prepared as described by the Jeppesen’s protocol (Jeppesen 2000) with slight 
modifications. Cells were first arrested at metaphase by incubation with 0.1 µg/ml 
colcemid (Gibco Invitrogen) under normal culture conditions for 8-12 hours depending 
on the cell growth rates. Cells were then harvested by trypsinization. Hypotonic KCl 
solution (75 mM) was then added to cells for 10 minutes at 37 oC for swelling. Following 
which, 5 × 104 cells were diluted with the KCl solution containing 0.1% Tween 20 (v/v) 
and cytocentrifuged at 1000 rpm for 5 minutes onto glass microscopic slides. After 
cytocentrifugation, slides were allowed to dry for a few minutes before being transferred 
to KCM solution (120 mM NaCl, 10 mM Tris HCl pH 7.5, 0.5 mM EDTA, 0.1% (v/v) 
Triton X-100) for 15 minutes at room temperature to solubilize cellular membranes. 
Antibody incubations were carried out in KCM with 10% normal serum to block non-
specific binding and slides were washed with KCM between primary and secondary 
antibody incubations. After incubation, slides were fixed with KCM containing 4% 
formaldehyde and finally washed with distilled water for 5 minutes before mounting with 
Vectashield with DAPI (Vectorlabs). Slides were then observed using Olympus Fluoview 




2.12 Transfection, virus production and cell infection 
The following plasmids were used for transfection and virus production. 
 
 
Figure 2.1 Plasmid constructs used for virus production. A. lentiviral packaging plasmid 
pCMV. B. Lentiviral enveloping plasmid pMD.G. C. Lentiviral shRNA NBS1, Addgene plasmid 
1864. D. Lentiviral CMV hTERT. E. Retroviral pBABE H-RAS V12, Addgene plasmid 9051. F. 
Retroviral pBABE E1A (the adenovirus early 1A region), Addgene plasmid 18742.   
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2.12.1 Transformation and amplification of plasmids 
Competent Escherichia coli cells were used for transformation. Thaw cells from -80 °C 
on wet ice. Add 1 μl plasmid into tubes containing competent cells (50 μl/tube) and tap 
tube to mix. Incubate the mixture on ice for 15 minutes. After incubation, put the mixture 
tube to 42 °C water bath for 90 seconds for heat shock. Place back the tube on ice for 3 
minutes. Add 200 μl lysogeny broth (LB) medium (without ampicillin) to the tube and 
shake the tube for 30 minutes at 30 °C. Take out the mixture in tube and spread onto LB 
plates (with ampicillin). Let plates dry at room temperature for 2 minutes before 
incubation for 24 hours at 32 °C for colony growth. Pick colonies into liquid LB medium 
(with ampicillin) to amplify the plasmids by shaking at 30 °C for 16 hours.  
Plasmid was then extracted from cells and purified using QIAprep Spin Miniprep Kit 
(Qiagen). Bacteria pellet was resuspended in 250 μl Buffer P1 in a microcentrifuge tube. 
Following this step, 250 μl Buffer P2 was added and mixed thoroughly by inverting the 
tube for 4-6 times. Before centrifugation, 350 μl Buffer N3 was added to mixture and 
mixed immediately by inverting the tube 4-6 times. Then centrifuge the tube for 10 
minutes at 13,000 rpm. Apply the supernatants to the QIAprep spin column by pipetting 
and centrifuge for 30-60 seconds. Discard the flow-through and add 0.75 ml Buffer PE to 
wash the column by centrifuging for 30-60 seconds. Discard the flow-through and 
centrifuge for an additional 1 minute to remove the residual wash buffer. After 
centrifugation, place the column in a clean 1.5 ml microcentrifuge tube. To elute DNA, 
add 50 μl Buffer EB or nuclease-free water to the center of each column and let it stand 
for 1 minute before centrifuging for 1 minute. The extracted plasmid DNA was stored at -
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30 °C freezer.  
2.12.2 Lentivirus production 
Plasmids with interested genes (12 μg), virus enveloping plasmid pMD.G (4 μg) and 
virus packaging plasmid pCMV (8 μg) were co-transfected into 293T cells cultured in 10 
cm dishes using Lipofectamine (Invitrogen) method. Medium that is used for transfection 
was Opti-MEM reduced serum medium (Invitrogen). Six or eight hours post transfection, 
medium was changed to DMEM. Virus was harvested in two batches (at 24 and 48 hours) 
and filtered using 0.45 μm filters. The virus were then stored at -80 °C in 1.5 ml aliquots.  
2.12.3 Retroviral production 
12 μg of plasmids were transfected into Pheonix cells cultured in 10 cm dishes using 
Lipofectamine method. Medium that is used for transfection was Opti-MEM reduced 
serum medium (Invitrogen). Six or eight hours post transfection, medium was changed to 
Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco, Invitrogen) supplemented with 
10% heat-inactivated FBS (without penicillin and streptomycin). Virus was harvested in 
two batches (at 24 and 48 hours) and filtered using 0.45 μm filters. The virus were then 
stored at -80 °C in 1.5 ml aliquots. 
2.12.4 Cell infection 
For cell infection, 1.5 ml virus with 0.5 ml DMEM (without penicillin and streptomycin) 
and 2 μl polybrene (8 mg/ml) were added to cells cultured in 6-well plates with ~70% 
confluency. Cells were incubated at normal culture condition for 24 hours before double 
infection was performed. After 2 days of infection, remove medium with virus particles 
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and add fresh DMEM medium and culture for 24 hours before selection with appropriate 




2.13 Soft agar assay/Anchorage-independent growth assay 
Infected cells were seeded into each well of a 24-well plate with a density of 1 × 105 
cells/well. The cells were embedded into 0.3% (w/v) noble agar (Sigma-Aldrich) in 
DMEM supplemented with 16.66% FBS, over a substratum of 0.6% noble agar in 
DMEM supplemented with 10% FBS. Fresh medium was added weekly and the agar 
plate was observed for colony formation for 6 weeks. At the end of 6 weeks, the colonies 
from each well were counted under microscope. Tumorigenicity of different samples was 





3.1 NBS1 deficiency does not affect the expression of MRE11 and RAD50 
In this study, cells derived from NBS patients who have typical 657del5 mutation of the 
NBS1 gene were used. As controls, normal cells with wild type NBS1 gene were also 
employed and paired with NBS cells under the criteria of age, gender and race for a more 
reliable comparison. As shown, the wild type NBS1 protein was only expressed in normal 
cells but not in NBS cells (Figure 3.1A), which corresponds to the notion that the 657del5 
mutation abolishes the expression of full length NBS1 protein (Maser, Zinkel et al. 2001). 
We further checked the expression level of another two components that consist of MRN 
complex, MRE11 and RAD50, in NBS cells as well as in normal cells. Results showed 




Figure 3.1 NBS1 deficiency does not affect the expression of MRE11 and RAD50. A. The 
expression of NBS1 protein in NBS fibroblasts as well as in age, race and gender-matched normal 
fibroblasts. The four cell lines were classified into two pairs, nominated as Pair 1 and Pair 2. 
GAPDH serves as the loading control. B. the expression of MRE11 and RAD50 in NBS 
fibroblasts as well as in normal fibroblasts. GAPDH serves as the loading control. 
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Figure 3.2 NBS1 deficiency affects ATM phosphorylation. A. The expression and 
phosphorylation level of ATM in NBS fibroblasts as well as in normal fibroblasts. Cells were 
treated with 1 µM Dox and collected at the time points indicated. Arrow indicates the band that 
represents pS1981-ATM. GAPDH serves as the loading control. B. The immunoblots in A were 
scanned and quantitated by densitometer, and the phosphorylation level of ATM was normalized 




To determine if NBS1 deficiency affects the phosphorylation of ATM, these two pairs of 
fibroblasts (Pair 1 and Pair 2) were then subjected to 1 µM Dox treatment and the 
phosphorylation level of ATM at Ser1981 was examined at different time points by 
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western blot. Results showed that ATM was quickly activated in normal cells and reached 
the highest level in 8 hours after Dox treatment (Figure 3.2A). However, in NBS cells, 
ATM phosphorylation was severely impaired, exhibited by a much lower level than that 
in normal counterparts (Figure 3.2B). Although ATM phosphorylation level decreased 
dramatically in NBS cells, there was still a basal level detectable (Figure 3.2A), 




3.3 NBS1 deficiency affects the phosphorylation of ATM downstream targets 
If NBS1 deficiency affects ATM activation, whether the activation of ATM downstream 
targets is also affected is the question that we want to address next. H2AX, p53 and Chk2 
are three important ATM downstream substrates that are involved in DNA damage 
response (Varon, Vissinga et al. 1998). The phosphorylation statuses of these three 
proteins were also examined by western blot. Results showed that the phosphorylation of 
H2AX at Ser139 and phosphorylation of p53 at Ser15 were also severely affected in NBS 
cells (Figure 3.3A). In normal cells, these two proteins were quickly phosphorylated to a 
high level and the high phosphorylation level was maintained for all the rest time points 
detected. But in NBS cells, the phosphorylation level was significantly decreased (Figure 
3.3A). Moreover, the total level of p53 was also affected in NBS cells, suggesting a 
possibility that NBS1 deficiency compromises p53 stability. The defects in 
phosphorylation of p53 were also observed in human breast cancer cells MCF7 with 
NBS1 knockdown (Figure S1). Surprisingly, the phosphorylation level of Chk2 at Thr68 
was not reduced in NBS cells, but only exhibited a delay in activation in pair 2. As shown, 
Chk2 was activated and reached a high level within 2 hours in normal cells, but was 
activated in NBS cells at a much later time point of 8 hours (Figure 3.3B). Taken together, 
these results suggest that NBS1 deficiency could affect the phosphorylation of ATM 







Figure 3.3 NBS1 deficiency affects the phosphorylation of ATM downstream targets. A. The 
phosphorylation of ATM downstream targets, including histone H2AX, p53 and Chk2. Cells 
were treated with 1 µM Dox and collected at the time points indicated. GAPDH serves as the 
loading control. B. The immunoblots of Chk2 and pT68-Chk2 were scanned and quantitated by 
densitometer, and the phosphorylation level of Chk2 was normalized to its total protein level. 
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3.4 NBS1 deficiency also affects ATR phosphorylation and the phosphorylation of 




Figure 3.4 NBS1 deficiency affects the phosphorylation of ATR as well as its downstream 
target Chk1. A. The expression and phosphorylation of ATR in Pair 2. Cells were treated with 1 
µM Dox and collected at the time points indicated. α-tubulin serves as the loading control. The 
immunoblots of ATR and pS428-ATR were scanned and quantitated by densitometer, and the 
phosphorylation level of ATR was normalized to its total protein level. B. The phosphorylation of 
ATR downstream target Chk1 in Pair 2. Cells were treated with 1 µM Dox and collected at the 
time points indicated. Phosphorylation of Chk1 at Ser317 was detected. GAPDH serves as the 
loading control. The immunoblots of Chk1 and pS317-Chk1 were scanned and quantitated by 
densitometer, and the phosphorylation level of Chk1 was normalized to its total protein level. 
 
 
The phosphorylation status of ATR upon Dox treatment was also investigated. As shown 
by western blot (Figure 3.4A), normal cells exhibited ATR phosphorylation at Ser428 
even without Dox treatment. When exposed to 1 µM Dox, the phosphorylation level in 
normal cells increased and reached a peak in 4 hours. But NBS cells only showed a subtle 
increase when subjected to Dox and the phosphorylation level was much lower than that 
in normal counterparts (Figure 3.4A). This result suggests that NBS1 deficiency also 
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compromises the phosphorylation of ATR. In addition to ATR, we also observed a 
decrease in the induction level of TOPBP1 (Figure S2). Since TOPBP1 is crucial in 
activation of ATR and the initiation of ATR-dependent signaling pathway (Kumagai, Lee 
et al. 2006; Choi, Lindsey-Boltz et al. 2009), we suggested that the decrease in ATR 
phosphorylation was due to the reduction in TOPBP1 level. Chk1, a direct downstream 
target of ATR (Zhao and Piwnica-Worms 2001), also showed impaired phosphorylation 
at Ser317 in NBS cells (Figure 3.4B). Collectively, NBS1 deficiency affects both ATR 








Figure 3.5 NBS1 deficiency delays inhibition of DNA synthesis after DNA damage occurs. A. 
The expression of NBS1 protein in NBS B-lymphocytes as well as in age, race and gender-
matched normal B-lymphocytes. The four cell lines were classified into two pairs, nominated as 
Pair 3 and Pair 4. GAPDH serves as the loading control. B. Cells were seeded into 96-well plate 
and after culturing for 2 days, cells were treated with 1 µM Dox and 10 µM BrdU at the same 
time for either 10 or 22 hours. The bar represents the ratio of Dox-treated BrdU+ cells to untreated 
BrdU+ cells. Data are mean ± S.D. from triplicates. (*, P ≤ 0.05) 
 
DNA damage response could lead to inhibition of DNA synthesis to stop the propagation 
of “bad” cells with DNA lesions. We next investigated the potential roles of NBS1 in 
eliciting inhibition of DNA synthesis when DNA is damaged. Since pair 2 fibroblasts are 
transformed with simian virus 40 which would render G1/S checkpoint inactive and 
therefore affect the number of cells entering S phase for DNA synthesis (Petrini, Attwooll 
et al. 2009), we used additional 2 pairs of B-lymphocytes for analysis of DNA synthesis 
status (Pair 3 and Pair 4).  As shown in the western blot, full length NBS1 was only 
expressed in normal cells but not in NBS cells (Figure 3.5A). Furthermore, similar as the 
phenotypes shown in NBS fibroblasts, the ATM-dependent phosphorylation events, such 
as phosphorylation of histone H2AX, p53 and Chk2, were also impaired in NBS B-
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lymphocytes (Figure S3).  
BrdU incorporation assay was employed to assess the proliferation profile of cells after 1 
µM Dox treatment for either 10 or 22 hours. From this result, we found that the cell 
proliferation was suppressed after Dox treatment in both normal and NBS cells, exhibited 
by the ratio of BrdU+Dox+ cells to BrdU+Dox- cells less than 1 (Figure 3.5B). Although 
suppression of cell proliferation was observed in both normal and NBS cells, at 10 hours, 
NBS cells showed a lesser degree of arrest than the normal cells, indicated by a higher 
BrdU+Dox+ to BrdU+Dox- cells ratio. It was only after 22 hours of Dox treatment, did the 
NBS cells exhibit a similar degree of arrest as their normal counterparts (Figure 3.5B). 
This result indicates the suppression of proliferation in NBS cells is not as efficient as 




3.6 NBS1 deficiency affects the initiation of apoptosis 
 
 
Figure 3.6 NBS1 deficiency affects the initiation of apoptosis. A. FITC Annexin V apoptosis 
assay. B-lymphocytes were treated with Dox at the indicated concentrations for 24 hours. The 
number of apoptotic cells was analyzed by flow cytometry. B. Quantitation of the percentage of 
apoptotic cells (including early and late apoptotic cells) shown in A. Data are mean ± S.D. from 
3 independent experiments. C. Western blot analysis of apoptosis-related proteins, including 




Another cellular event of DNA damage response is to initiate apoptosis when DNA 
damage is beyond repair. Cells treated with different concentration of Dox for 24 hours 
were harvested and subjected to flow cytometry analysis. Results showed that NBS cells 
had comparable apoptosis level to normal cells under lower concentration of Dox 
treatment. When the concentration of Dox was increased to a high concentration of 0.5 
µM (in pair 4) or 1 µM (in pair 3), normal cells exhibited elevated level of apoptosis. 
However, the apoptosis level in NBS cells remained low as that under lower 
concentrations of Dox treatments (Figure 3.6A & B), indicating that NBS cells were 
defective in inducing apoptosis when cells were exposed to high dosage of Dox. Western 
analysis of apoptosis associated markers showed that cleaved caspases 3 almost 
diminished in NBS cells. However, as a direct downstream target of caspases 3 
(Simbulan-Rosenthal, Rosenthal et al. 1998), PARP only exhibited a minor decrease in its 
cleaved form in NBS cells (Figure 3.6C). This is probably due to the low level of cleaved 
caspases 3 in NBS cells. The low efficiency in cleavage of these proteins may be 
responsible for the defects of NBS cells in initiation of apoptosis under high 




3.7 NBS1 deficiency promotes telomere shortening and an earlier onset of 






Figure 3.7 NBS1 deficiency leads to accelerated telomere shortening and an earlier onset of 
senescence in NBS fibroblasts. A. Measurement of the telomere restriction fragment length. 
Genomic DNA isolated from normal and NBS fibroblasts at indicated PDLs were analyzed. B. 
Telomere shortening rate in normal and NBS fibroblasts. Data are mean ± S.D. from duplicate 
experiments. Telomere shortening rate (slope of the regression line) and Spearman’s regression 
coefficient are indicated. C. Cellular senescence assay in fibroblasts using β-galactosidase 
staining. Arrows indicate senescent cells. D. Bars represent the percentage of β-
galactosidase positive cells. Data are mean ± S.D. from 5 images each.  
 
Premature aging has been observed in NBS fibroblasts in vitro (Ranganathan, Heine et al. 
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2001). Premature cellular senescence could be elicited by accelerated telomere shortening. 
We therefore asked whether NBS1 deficiency elicits premature aging through regulating 
telomere attrition rate. Telomere length of the two pairs of fibroblasts was tested by the 
Terminal Restriction Fragment southern blot. Result showed that the telomere length of 
NBS fibroblasts was generally shorter than that of age-matched normal fibroblasts, which 
probably represents the long-term accumulative effect of an accelerated telomere 
shortening rate of NBS cells in vivo. When comparing the telomere attrition rate with 
each replication cycle in vitro, we found that NBS fibroblasts indeed had a higher 
telomere shortening rate compared to that in normal fibroblasts (Figure 3.7A). For each 
replication cycle, the telomere shortening rate of NBS fibroblasts was around 30 bp faster 
than that of its respective normal counterparts (Figure 3.7B). This result strongly 
indicates that NBS1 plays a role in telomere length maintenance and the deficiency of 
NBS1 leads to faster telomere attrition.  
We performed β-galactosidase assay to study the senescence status of normal as well as 
NBS fibroblasts in vitro. Cells were cultured to the same PDL and stained, and the cells 
stained blue were counted as senescent cells. Consistent with the accelerated telomere 
shortening, NBS fibroblasts exhibited a significantly higher percentage of cells 
undergoing senescence compared to normal cells with the same PDLs (Figure 3.7C & D). 





3.8 NBS1 deficiency leads to an earlier onset of cell death in B-lymphocytes 
Progressive telomere shortening in the absence of telomerase would eventually trigger 
DNA damage responses and lead to replicative senescence or senescence-associated 
apoptosis (Blasco 2005). In this regard, accelerated telomere shortening could not only 
lead to earlier onset of senescence, but also lead to earlier occurrence of senescence-
associated apoptosis in cells. In order to examine the role of NBS1 in induction of 
senescence-associated apoptosis, the two pairs of B-lymphocytes were cultured in vitro 
till late passages and subjected to flow cytometry analysis. Results showed that NBS B-
lymphocytes had a higher percentage of cells undergoing apoptosis compared to normal 
counterparts when cultured to similar or even lower PDLs (Figure 3.8A & B), indicating 
NBS1 deficiency leads to earlier and more severe senescence-associated apoptosis.  
This result was corroborated by microscopy images of NBS B-lymphocytes which 
showed prevalent cell debris under normal culture conditions, while normal B-
lymphocytes remained spherical even at higher PDLs, suggesting a healthy growing 
status (Figure 3.8C). The growth curve demonstrated the trend of replication and 
apoptosis status of NBS B-lymphocytes over 18 days. As shown (Figure 3.8D), the 
growth rate of NBS B-lymphocytes is comparative to that of normal cells at the early 
days of cell culture. But at later days, the number of NBS B-lymphocytes ceased 
increasing and even started to decrease, probably indicating the onset of cellular 
senescence and cell death in these cells. By contrast, normal B-lymphocytes only had a 
slight decrease in cell growth rate even at later days, suggesting a healthy cell replication 





  Figure 3.8 NBS1 deficiency leads to an earlier onset of cell death in B-lymphocytes. A. FITC 
Annexin V apoptosis assay. B-lymphocytes were cultured to late passages under normal culture 
condition without drug treatment. The number of apoptotic cells was analyzed by flow cytometry. 
B. Quantitation of the percentage of apoptotic cells (including early and late apoptotic cells) 
shown in A. C. Cellular morphologies of B-lymphocytes at late passages. Circles enclose the 
dead cell debris. D. Growth curve of B-lymphocytes. Cells were split and counted every other day 
over 18 days. The accumulative cell number was shown against days.   
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Figure 3.9 NBS1 deficiency does not lead to accelerated telomere shortening in NBS B-
lymphocytes.  A. Measurement of the telomere restriction fragment length. Genomic DNA 
isolated from normal and NBS B-lymphocytes at indicated PDLs were analyzed. B. 
Telomere shortening rate in normal and NBS B-lymphocytes. Telomere shortening rate 
(slope of the regression line) and Spearman’s regression coefficient are indicated. 
 
The earlier onset of senescence-associated apoptosis could be driven by accelerated 
telomere attrition which would result in the faster generation of cells with critically short 
telomeres. Therefore, telomere length of the two pairs of B-lymphocytes was tested by 
the Terminal Restriction Fragment southern blot. However, the shortened telomeres were 
only observed in the NBS B-lymphocytes of Pair 4, but not in the one of Pair 3 (Figure 
3.9A). Furthermore, when comparing the telomere shortening rate with each replication 
cycle, a lower rather than a higher telomere shortening rate was detected in both NBS B-
lymphocytes (Figure 3.9B), suggesting that NBS1 deficiency does not cause accelerated 
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telomere shortening in B-lymphocytes. The earlier occurrence of senescence-associated 
apoptosis observed in NBS B-lymphocytes is probably due to other mechanisms. 
Moreover, this result suggests that the extremely short telomere length observed in NBS 
B-lymphocytes of Pair 4 is not because of accelerated telomere attrition, but probably due 
to their long proliferation history in NBS patients before isolated. 








Figure 3.10 Real-time PCR for relative telomerase activity in NBS versus normal fibroblasts. 
Cells with similar PDLs were lysed in TeloExpress lysis buffer and the supernatant containing 




Telomere length is maintained by the activity of telomerase. Although it is generally 
thought that human primary fibroblasts lack telomerase activity, transient expression of 
telomerase has been reported in human fibroblasts (Masutomi, Yu et al. 2003). We next 
investigated whether telomerase is involved in the regulation of telomere shortening rate 
in NBS fibroblasts. Telomerase activity of NBS fibroblasts was compared with normal 
counterparts by real-time PCR. Results showed that NBS fibroblasts have comparative 
telomerase activity to normal counterparts (Figure 3.8), suggesting that the accelerated 




3.11 NBS1 deficiency leads to upregulation of TRF2 in fibroblasts 
Shelterin complex proteins protect the telomere integrity, but it also has been claimed that 
these proteins are negative regulators for telomere length (de Lange 2005). We next 
looked into the different components of shelterin complex and found that the cellular 
level of TRF2 was upregulated in NBS fibroblasts (Figure 3.9A). However, the 
expression of other shelterin components, including TRF1, RAP1 and POT1, did not 
show obvious changes (Figure 3.9B). RT-PCR confirmed this result by showing an 
upregulation of TRF2 at mRNA level (Figure 3.9C). The overabundance of TRF2 at 
telomere ends may negatively regulate telomere length, resulting in accelerated telomere 
shortening in NBS fibroblasts.  
 
Figure 3.11 NBS1 deficiency leads to upregulation of TRF2. A. Western blot analysis of the 
TRF2 protein level in NBS fibroblasts as well as in normal counterparts with similar PDLs. The 
numbers above the blot indicate its fold difference measured by densitometer with normal cell’s 
TRF2 protein level being set at a reference value of 1. β-actin serves as the loading control. B. 
Western blot analysis of the other shelterin complex proteins in NBS and normal fibroblasts, 
including TRF1, POT1 and RAP1. GAPDH serves as the loading control. C. RT-PCR analysis of 
the TRF2 mRNA level in NBS and normal fibroblasts. mRNA was extracted from fibroblasts 
with similar PDLs and used in one-step RT-PCR analysis. The numbers above the blot indicate its 
fold difference measured by densitometer with normal cell’s TRF2 protein level being set at a 
reference value of 1. 
 79 
 




Figure 3.12 NBS1 deficiency does not affect the expression level of TRF2 in B-lymphocytes. 
Western blot analysis of the protein levels of all the six components of shelterin complex, 
including TRF1, TRF2, POT1, RAP1, TIN2 and TPP1 in NBS B-lymphocytes as well as in 
normal ones with similar PDLs. GAPDH serves as the loading control.  
 
 
The expression levels of shelterin components in NBS B-lymphocytes were also detected 
by western blots. However, TRF2 protein level was not altered in NBS B-lymphocytes 
within each pair. And the expression levels of the rest five components of shelterin 
complex, including TRF1, POT1, RAP1, TPP1 and TIN2, also did not show alterations in 
the condition of NBS1 deficiency (Figure 3.12). These results further manifest that the 
same type of NBS1 mutation would cause different defects at telomeric ends in 








Figure 3.13 NBS1 deficiency leads to chromosome instabilities. A. Metaphase spreads of Pair 
1 fibroblasts were stained with antibodies against TRF2 (green) and visualized by 
immunofluorescence. DNA was stained with DAPI (blue). Arrows point to telomeric end fusions. 
The insets (a and b) are representatives of telomeric fusions. B. Bars represent the percentage of 
cells that are positive with telomeric fusions. The total cell number is 25. C. Bars represent the 
average number of chromosomes enumerated from the metaphase spreads. Data are mean ± S.D. 




The accelerated telomere shortening and dysregulation of shelterin complex components 
may jeopardize the stability of telomeres in NBS cells. To evaluate the integrity of 
telomeres of NBS cells, we performed cytogenetic analysis of metaphase spread to 
investigate directly at the chromosome ends. As shown, prevalent telomere associations 
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were observed in NBS fibroblasts (Figure 3.13A), exhibited by telomeres of different or 
the same chromosomes exist in unusually close proximity. Although very rare, telomere 
fusions were also observed in normal cells (Figure 3.13B). Telomere associations affect 
the chromosome separation during mitosis, resulting in aneuploid cells. We found that 
most of the normal cells retain 46 chromosomes during culture in vitro, although few of 
them showed abnormal chromosome numbers that slightly deviate from 46 (Figure 
3.13C). In contrast, NBS cells showed an average chromosome number of 78 which 
significantly deviates from the normal chromosome number, suggesting that the 








Figure 3.14 NBS1 does not promote malignant transformation of fibroblasts in vitro. A. 
Western blot analysis of the protein level of hTERT, H-RAS and p53 in normal as well as in NBS 
fibroblasts infected with virus particles containing hTERT, E1A and H-RAS V12 gene. Arrow 
indicates the band of Flag-hTERT. B. The representative images of colonies formed in soft agar 
plates containing transformed cells. C. Quantification of the colony formation efficiency of 
different cell lines. Human colon cancer cells HCT116 serve as the positive control. The colony 
formation efficiency equals the average number of colonies in one well divided by the total cells 




DNA damage response and telomere integrity maintenance are two important aspects in 
preventing malignant transformation of cells in the early stage of cancer (Bartek, Lukas et 
al. 2007). Having observed defects in both of these aspects in NBS fibroblasts, it seems to 
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be apparent that NBS fibroblasts are more prone to malignant transformation than normal 
cells. To test this hypothesis, soft agar assay which detects and measures the 
morphological transformation of cells was performed. Normal as well as NBS fibroblasts 
were infected with viruses containing plasmid hTERT, H-RAS V12 and E1A, 
simultaneously. The successfully transfected clones are subjected to soft agar assay. Due 
to the difficulty in getting transfected clones of AG09309, another normal fibroblast 
GM01864 was used as control of NBS fibroblast GM07166. As shown (Figure 3.14A), 
hTERT and H-RAS V12 were successfully transfected into cells. As E1A overexpression 
leads to accumulation of p53 (Querido, Teodoro et al. 1997), we also detected the protein 
level of p53 to reflect the transfection efficiency of E1A. However, p53 level was only 
upregulated in normal fibroblasts but not in NBS fibroblasts, suggesting that E1A-
induced p53 accumulation may be NBS1-dependent. The transfected cells were then 
seeded into agar plates and incubated for 6 weeks. Colonies were observed in both of the 
transfected cell lines although with a lower efficiency compared to the positive control 
HCT116, suggesting that transfected cells had less tumorigenicity (Figure 3.14B). 
Surprisingly, no obvious difference in the colony formation efficiency was observed 
when comparing NBS to normal fibroblasts (Figure 3.14C). This result indicates that 
NBS1 deficiency does not promote the malignant transformation of fibroblasts even 








4.1 NBS1 deficiency affects the DNA damage response  
The NBS1 gene encodes a 95 KD protein (Difilippantonio and Nussenzweig 2007). The 
657del5 mutation of this gene leads to a frame shift and premature termination at codon 
219 which abolishes the expression of full length NBS1 (Maser, Zinkel et al. 2001). It is 
predicted that the premature termination would result in the expression of two truncated 
proteins, the 26 KD N-terminus and the 70 KD C-terminus (Tauchi, Matsuura et al. 2002). 
The NBS1 antibody used in this study recognizes C-terminal residues of human NBS1. 
However, the 70KD C-terminus was not observed (data not shown). Maser and 
colleagues also  reported that only the 26 KD fragment, but not the 70 KD one, was 
found in NBS fibroblasts (Maser, Zinkel et al. 2001).  The 70 KD C-terminus of NBS1 
contains the region that binds to MRE11 which is necessary for the nuclear localization 
of MRE11/RAD50 and the formation of functional MRN complex (Kobayashi, Antoccia 
et al. 2004). Our results showed that although the absence of NBS1 C-terminus in NBS 
fibroblasts, the expression level of another two components of MRN complex were not 
affected.   
It has been proved in Xenopus egg extracts that the C-terminus of NBS1 is essential for 
recruiting ATM to damaged DNA where its subsequent autophosphorylation occurs (You, 
Chahwan et al. 2005). Our results demonstrated that in the absence of full length NBS1 
and its C-terminus, ATM phosphorylation at Ser1981 was diminished in NBS cells when 
exposed to Dox treatment. This result indicates that NBS1 is not only a downstream 
substrate of ATM (Lim, Kim et al. 2000), but also serves as an upstream regulator that 
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mediates the phosphorylation and activation of ATM. However, NBS cells still retain a 
low level of ATM phosphorylation under Dox treatment. We suggest that ATM 
autophosphorylation exists in a low basal level in cells that are under DNA damage even 
without functional NBS1. NBS1 serves as an amplifier for ATM activity which facilitates 
ATM to reach a threshold maximal activity when DNA damage occurs (Horejsi, Falck et 
al. 2004). 
Lying in the crossroad of DNA damage signaling pathway, ATM mediates diverse 
responses through phosphorylation on different downstream targets. Histone H2AX is 
one of them. We found that NBS1 deficiency severely affects the phosphorylation of 
histone H2AX at Ser139 in response to Dox treatment. p53 is another ATM target which 
plays multifaceted role in DNA damage response. We also observed that p53 
phosphorylation is seriously impaired in NBS cells. Although the phosphorylation of 
ATM downstream substrates H2AX and p53 was severely affected, we could still observe 
a basal level of phosphorylation and activation of these proteins. This result suggests that 
NBS1 deficiency does not fully abolish the phosphorylation of  ATM targets, probably 
due to the existence of a basal level of ATM phosphorylation. However, the activation of 
Chk2 was apparently normal though slightly delayed in NBS cells under Dox treatment. 
Like p53, Chk2 could also be phosphorylated by ATM and functions in cell cycle arrest. 
The phosphorylation of Chk2 brings its catalytic domain into the close proximity of 
another Chk2 molecule that allows auto-trans-phosphorylation to occur (Oliver, Knapp et 
al. 2007). In NBS cells, although impaired, ATM activation was still present at basal 
levels. It could be explained that the basal level of activated ATM is sufficient to elicit 
initial phosphorylation of Chk2 which creates conditions for its following auto-trans-
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phosphorylation. But this process may take longer time than the direct phosphorylation of 
Chk2 by ATM, so that NBS cells showed a delay in Chk2 phosphorylation. Although pair 
1 and pair 2 generally exhibited similar trends, differences between these 2 pairs did exist, 
such as p53 expression level and Chk2 phosphorylation level. The differences between 
pair 1 and pair 2 may due to the transformation of SV40 in pair 2 cells. SV40 may 
activate DNA damage signaling pathway even without Dox treatment, causing 
differential protein expression and phosphorylation profiles between pair 1 and pair 2.  
As a DNA intercalating agent, Dox not only causes DSBs, but also inhibits cell 
proliferation and DNA synthesis by generating stalled replication forks (Kim, Lee et al. 
2009) which could be repaired by ATR-dependent signaling pathway (Stiff, Reis et al. 
2005). Indeed, we found that when subjected to Dox treatment, ATR phosphorylation 
level increased in normal cells. However, the phosphorylation event was impaired when 
NBS1 is deficient. This result suggests that NBS1 is not only an upstream regulator of 
ATM, but also functions upstream of ATR.  
Recent years, several studies showed an essential role of TOPBP1 in activating ATR and  
eliciting ATR-dependent signaling events in both human cells and Xenopus egg extracts 
(Kumagai, Lee et al. 2006; Mordes, Glick et al. 2008; Choi, Lindsey-Boltz et al. 2009). It 
was further shown that NBS1 interacts with TOPBP1, a process that is essential for 
TOPBP1 to activate ATR (Yoo, Kumagai et al. 2009). In human NBS1-2A mutants 
(mutations within BRCT domain), TOPBP1 failed to bind to NBS1 which further affects 
ATR-dependent signaling processes, such as phosphorylation of Chk1 (Yoo, Kumagai et 
al. 2009). In line with this, our study showed a reduction in TOPBP1 expression level 
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when NBS1 is deficient, which is probably responsible for the impaired activation of 
ATR in NBS fibroblasts. Although the direct interaction between NBS1 and TOPBP1 has 
been reported, how NBS1 regulates the expression level of TOPBP1 remains to be 
determined.  
As a direct downstream substrate of ATR (Liu, Guntuku et al. 2000), Chk1 
phosphorylation level was also affected in NBS fibroblasts (Figure 3.4B). In addition, the 
total protein level of Chk1 was also severely compromised, suggesting that NBS1 
deficiency affects the stability of Chk1.  
All together, our results suggest that NBS1 is an upstream regulator of both ATM and 
ATR kinase. The deficiency of NBS cells in producing full length NBS1 renders them 
inefficient in activating these two kinases as well as their downstream substrates upon 
DNA damage. But either a lower level of phosphorylation or a delayed activation of 
proteins still exists in NBS cells, indicating that NBS1 deficiency could only partially 
affect the DNA damage signaling pathway.  
As an initial response when DNA damage occurs, normal cells with intact DNA damage 
signaling pathway would arrest to allow DNA damage to be repaired (Kastan and Bartek 
2004). Different cell cycle arrest mechanisms are required in response to DNA damage in 
a cell-type and DNA-damage specific manner. All three types of cell cycle arrest, 
including G1/S, intra-S and G2/M arrest, have been reported in human cells treated with 
Dox although in a cell-type specific manner (Robles, Buehler et al. 1999; Lee, Youn et al. 
2005; Bar-On, Shapira et al. 2007). For example, human MCF7 cells exhibited G1/S and 
G2/M arrest when subjected to Dox treatment (Bar-On, Shapira et al. 2007), whereas 
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normal human F65 cells only showed G2/M arrest under the same drug treatment (Lee, 
Youn et al. 2005). How the kinases in DNA damage signaling pathway select and activate 
different substrates, thereby mediates cell-type specific responses, are still not fully 
resolved. But mutation of the genes in DNA damage signaling pathway will be one of the 
causes that affect the DNA damage response profile.  
NBS1 is involved in several signaling pathways that mediate cell cycle arrest. Mutation 
of NBS1 at ATM phosphorylation site (S343A mutation) resulted in a failure of S-phase 
arrest in response to IR in 293T cells (Lim, Kim et al. 2000). This phenomenon is known 
as radio-resistant DNA synthesis (RDS), in which cells continue DNA synthesis in the 
presence of IR-induced DNA damage. RDS was also observed in NBS cells with 657del5 
mutation (Kobayashi, Antoccia et al. 2004). Dox has similar effects with IR in terms of 
the damages that they could generate in cells (Lee, Youn et al. 2005). Consistent with 
previous reports, our data showed that in response to Dox treatment for 10 hours, NBS 
cells were deficient in inhibiting DNA synthesis. However, this defect was diminished 
after 22-hour treatment with Dox, by when NBS cells exhibited successful inhibition of 
DNA synthesis as that observed in normal cells. This result indicates that NBS1 
deficiency may delay the intra-S phase arrest, but does not abolish it.  
At least three parallel pathways involved in intra-S phase checkpoint have been reported, 
including the ATM/NBS1/SMC1 pathway (Yazdi, Wang et al. 2002), the ATM/CHK2/ 
CDC25A/CDK2 pathway (Falck, Petrini et al. 2002) and the ATM/FANCD2 pathway 
(Nakanishi, Taniguchi et al. 2002). Although it was previously thought that only the 
ATM/NBS1/SMC1 pathway is NBS1-dependent (Kobayashi, Antoccia et al. 2004), the 
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recent recognition of NBS1’s function as an upstream regulator of ATM suggest a 
dependency on NBS1 in all the three pathways. However, as shown by our study, NBS1 
deficiency did not fully abolish the phosphorylation of ATM and ATM-mediated 
downstream events. In particular, the phosphorylation of Chk2 was only delayed but not 
impaired in the phosphorylation level in the condition of NBS1 deficiency. This result 
probably provided an explanation for the delayed inhibition of DNA synthesis observed 
in NBS cells.  
Another cellular event that responds to DNA damage is apoptosis. Activation of apoptosis 
signaling pathway serves as an essential mechanism in removing damaged cells to 
maintain genome stability. One of the most important pathways that mediate apoptosis is 
the  ATM-Chk2-p53 pathway. Mutation or deletion of the genes involved in apoptosis 
signaling pathways would lead to defects in inducing apoptosis. A-T cells that are 
defective in ATM gene are more sensitive to IR and exhibit less apoptosis after IR than 
normal cells (Duchaud, Ridet et al. 1996). In addition, thymocytes derived from ATM 
knockout mice also exhibit a lower apoptosis level following IR than the corresponding 
wild type mice, indicating the importance of ATM in triggering apoptosis (Westphal, 
Rowan et al. 1997). Chk2 could phosphorylate p53 at additional Ser residues, including 
Ser15 and Ser20. It has been demonstrated that in cells expressing dominant negative 
Chk2 and mice with deficient Chk2, a defect in apoptosis was observed, suggesting Chk2 
also plays a role in mediating apoptosis in response to DNA damage (Rogoff, Pickering 
et al. 2004). NBS1 has also been reported participating in apoptosis pathway. It has been 
shown that the DNA-damage induced apoptosis level is significantly reduced in NBS 
cells in response to IR (Tauchi, Iijima et al. 2008).   
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Using annexin V apoptosis assay, we also observed a defect of NBS cells in inducing 
apoptosis. However, this defect only existed in cells exposed to high concentration of 
Dox treatment, but not in cells under low concentration. The concentration of Dox may 
be proportional to the amounts of DNA lesions caused. Under low concentration of Dox, 
small amount of DNA lesions are generated in cells. And as shown earlier, although the 
phosphorylation of ATM and the phosphorylation events elicited by ATM were either 
impaired or delayed in NBS cells, they still exhibited a basal level of phosphorylation or 
delayed activation. We speculate that the activated basal-level proteins are sufficient to 
encounter the small scale lesions caused by low concentration of Dox, but not enough to 
deal with the massive DNA damage caused by high concentration of Dox. This result 
suggests that the partially affected ATM signaling pathway in NBS cells could retain the 
apoptotic event to some degree but could not fully restore it when cells are under large 
scale of DNA damage.  
Caspases are the central components mediating apoptosis (Riedl and Shi 2004). Among 
them, caspases 3 is a frequently activated death executioner which catalyzes the specific 
cleavage of various key cellular proteins (Porter and Janicke 1999). Activation of 
caspases 3 is through cleavage by other initiator caspases (Li, Nijhawan et al. 1997). Our 
results showed that NBS1 deficiency severely affects the cleavage of caspases 3 in 
response to Dox treatment at different concentrations. However, this inefficiency in 
cleavage and activation of caspases 3 did not significantly affect the cleavage of its 
downstream targets, such as PARP.  Besides caspase 3, caspase 7 was also reported as an 
upstream regulator of PARP.  It is possible that caspase 7 activity was not affected in 
NBS cells and contributed to the cleavage of PARP.  Also, the unaffected PARP could be 
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due to the basal level of cleaved caspase 3 in NBS cells. However, the molecular 
mechanism of how NBS1 mediates the apoptotic signal to caspases therefore inducing 
apoptosis still remains to be elucidated.  
Taken together, our results suggested that NBS1 was involved in ATM/ATR-midiated 
DNA damage signaling pathway. Deficiency of NBS1 affected ATM/ATR 
phosphorylation as well as their downstream effectors, leading to defects in apoptosis and 
DNA synthesis (Figure 4.1). 
 






4.2 NBS1 deficiency compromises telomere integrity 
NBS1 have been shown to directly bind to telomeres (Zhu, Kuster et al. 2000; Dimitrova 
and de Lange 2009). The binding of NBS1 to telomeres suggests a role of this protein in 
protecting telomere integrity. Besides NBS1, many other proteins that are involved in 
DNA damage response are found associated with telomeres, such as ATM and the other 
two components of MRN complex, MRE11 and RAD50 (Munoz, Blanco et al. 2006). 
Many of the telomere-associated proteins are mutated in human genomic instability 
syndromes that are characterized by premature aging and shortened telomeres (Blasco 
2005). Premature aging is always attributed to accelerated telomere shortening of cells. 
For example, A-T cells that are derived from A-T patients featured by premature aging 
show accelerated shortening of telomeres (Metcalfe, Parkhill et al. 1996). Our study 
using NBS fibroblasts derived from NBS patients with 657del5 mutation showed that 
NBS fibroblasts also have shorter telomeres than normal counterparts. When comparing 
the telomere shortening rate in vitro, we observed that NBS fibroblasts have a higher 
telomere attrition rate with each replication cycle. This result extends our recognition of 
NBS’s role at telomeric ends.   
However, the accelerated telomere attrition was not observed in NBS B-lymphocytes 
with the same mutation type of NBS1. One possible explanation to account for the 
different effects of NBS1 mutation in NBS fibroblasts and NBS B-lymphocytes is the fact 
that the expression of NBS1 truncated fragments, the 26 KD N-terminus and the 70 KD 
C-terminus, are differentially expressed in these two types of cells. Although the 26 KD 
fragment is expressed in both NBS fibroblasts and B-lymphocytes, the 70 KD fragment is 
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only detected in B-lymphocytes but not in fibroblasts (Maser, Zinkel et al. 2001). The 70 
KD fragment physically interacts with MRE11/RAD50 complex and is essential for their 
nuclear localization and MRN complex formation (Desai-Mehta, Cerosaletti et al. 2001). 
This process may be important for the recruitment of MRN complex from cytoplasm to 
telomeres to partially restore its function at telomeric ends, such as regulation of telomere 
shortening rate. But this possibility has not been tested and other causes that may lead to 
the difference in telomere shortening rate between NBS fibroblasts and B-lymphocytes 
need to be determined.  
Accelerated telomere shortening will result in the earlier occurrence of critically short 
telomeres which would further elicit cellular senescence (Hezel, Bardeesy et al. 2005). 
We observed premature cellular senescence in NBS fibroblasts, as showed by β-
galactosidase assay, which corroborates with the finding of accelerated telomere attrition 
in these cells. Although NBS B-lymphocytes did not show telomere shortening defects, 
we did observe an earlier onset of senescence-associated apoptosis in these cells under 
normal cell culture conditions. The occurrence of senescence-associated apoptosis could 
be induced by shortened and unstable telomeres (Blasco 2005). Thus, it is possible that 
NBS1 deficiency could lead to telomeric abnormalities other than accelerated telomere 
shortening, even though with the presence of the 70 KD C-terminus.  
Telomerase is required to extend telomere length and prevent telomere attrition in most 
cell types, except cancer cells that use ALT mechanism (Henson, Neumann et al. 2002). 
Thus, lack of telomerase activity may be the cause for the accelerated telomere 
shortening in NBS fibroblasts. However, our result that NBS and normal fibroblasts 
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showed similar level of telomerase activity excludes this possibility, indicating that the 
accelerated attrition of telomeres is caused by other mechanisms.  
As mentioned earlier, A-T cells that are mutated in ATM gene also exhibited accelerated 
telomere shortening (Metcalfe, Parkhill et al. 1996). It has been proposed that this defect 
in A-T cells is caused by a decreased accessibility of telomerase to telomeres (Wu, Xiao 
et al. 2007). ATM, as a protein kinase, can phosphorylate TRF1, a process that will 
reduce the binding ability of TRF1 to telomeres. The reduction in TRF1 binding level at 
telomeric ends facilitates the assembly of telomerase to telomeres and leads to 
telomerase-dependent telomere elongation (Wu, Xiao et al. 2007). Therefore, ATM 
mutation would exert a negative effect in the telomere elongation by reducing the 
accessibility of telomerase to telomeres, which may further lead to accelerated telomere 
shortening observed in A-T cells. With regard to the close relationship between NBS1 
and ATM, it is possible that NBS1 also protects telomere from accelerated telomere 
shortening through the regulation of the accessibility of telomerase to telomeres.   
This model provides some hints to study the accelerated telomere shortening in A-T and 
NBS cells not only from the aspect of telomerase but also from the area of shelterin 
complex. The speculation of the relationship between shelterin complex and accelerated 
telomere shortening is strengthened by the fact that shelterin complex components are 
negative regulators of telomere length (vanSteensel and deLange 1997; Smogorzewska, 
Van Steensel et al. 2000; O'Connor, Safari et al. 2004; de Lange 2005; Munoz, Blanco et 
al. 2009). TRF1 and TRF2 are the two most frequently investigated shelterin components 
at telomeric ends. It has been well established that TRF1 and TRF2 expression level plays 
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an important role in determining telomere shortening rate (vanSteensel and deLange 1997; 
Richter, Saretzki et al. 2007). Overexpression of TRF1 or TRF2 leads to accelerated 
telomere shortening in vitro and premature aging in vivo (Munoz, Blanco et al. 2006; 
Munoz, Blanco et al. 2009).  
Our results showed that TRF2 was upregulated at both mRNA and protein level in 
fibroblasts with NBS1 deficiency. However, the expression level of TRF1 was not 
affected by NBS1 deficiency but maintained at the similar level as that in normal 
fibroblasts. The upregulation of TRF2 may contribute to the accelerated telomere 
shortening observed in NBS fibroblasts. TRF2 has also been reported as a substrate of 
ATM with a phosphorylation site at Thr188 (Huda, Tanaka et al. 2009). It is possible that 
the phosphorylated TRF2 has a similar mode with the phosphorylated TRF1 which would 
dissociate from telomeres and facilitate telomerase-dependent telomere elongation 
(Figure 4.2A). However, NBS1 deficiency affects ATM phosphorylation, which may 
further impair the phosphorylation of TRF2 by ATM. Un-phosphorylated TRF2 might 
accumulate to a high level and remain associated with telomeres, thereby preventing the 






Figure 4.2 Model for NBS1- and ATM-mediated phosphorylation of TRF2 in modulating 
telomerase-dependent telomere elongation. A. NBS1 mediates the optimal phosphorylation of 
ATM, a process that contributes to the phosphorylation of TRF2. Phosphorylated TRF2 
dissociates from telomeres which facilitates the access of telomerase to telomeric ends and leads 
to telomerase-dependent telomere elongation. B. When NBS1 is mutated, the process of ATM 
auto-phosphorylation is affected, leading to incompetence in TRF2 phosphorylation. 
Unphosphorylated TRF2 remains associated with telomeres, thereby preventing the access of 
telomerase to telomeres and telomerase-dependent telomere elongation.  
 
Recently, a new feedback loop between p53 and TRF2 during cellular senescence has 
been reported. Cellular senescence activates the canonical DNA damage signaling 
pathway that engages p53 to initiate replicative senescence or senescence-associated 
apoptosis (Deng, Chan et al. 2008). During this process, activated p53 induces the 
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expression of Siah1, a p53-inducible ubiquitin ligase that is capable of ubiquitinating 
TRF2 and leads to proteasomal-mediated degradation of TRF2 (Figure 4.3A) (Fujita, 
Horikawa et al. 2010). However, NBS1 deficiency affects the activation of p53, which 
may subsequently influence the induction of Siah1. It has been shown that inhibition of 
Siah1 stabilizes TRF2 and results in TRF2 accumulation (Fujita, Horikawa et al. 2010). If 
NBS1 deficiency affects Siah1 level, TRF2 degradation would also be affected. As a 
result, an accumulated higher TRF2 level would be expected in NBS cells. It is possible 
that the access of telomerase to telomeres is blocked due to the accumulated TRF2 level, 




Figure 4.3 Model for p53-dependent ubiquitination of TRF2 in modulating telomerase-
dependent telomere elongation. A. p53 is activated during cellular senescence. Activated p53 
induces the expression of Siah1, a ubiquitin ligase that is capable of ubiquitinating TRF2. 
Ubiquitinated TRF2 is subjected to proteasomal-mediated degradation. B. When NBS1 is mutated, 
the optimal phosphorylation of ATM is affected, which further affects the phosphorylation and 
activation of p53. As a result, Siah1 induction level is also impaired, leading to TRF2 
accumulation at telomeres rather than being degraded. Accumulation of TRF2 prevents the the 
access of telomerase to telomeres and telomerase-dependent telomere elongation.  
 
Why NBS1 deficiency selectively upregulates TRF2 but not TRF1 also remains unknown. 
We speculate that the difference between TRF1 and TRF2 in terms of their functions at 
telomeric ends may be the leading cause for the differential regulation of their expression 
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level in NBS fibroblasts. Although TRF1 and TRF2 have similar function and binding 
mode to telomeric DNA, TRF2 plays an important role in T-loop formation that protects 
telomere integrity (Nishimura, Hanaoka et al. 2005). Furthermore, TRF2 has been shown 
to interact with MRN complex and maintain telomere integrity in a combination effort 
with ATM (Zhu, Kuster et al. 2000; Dimitrova and de Lange 2009). The difference 
between TRF1 and TRF2 may be the reason why TRF2 is affected in the condition of 
NBS1 deficiency, but not TRF1. 
In line with the observation that NBS1 deficiency does not lead to accelerated telomere 
shortening in NBS B-lymphocytes, we also did not observe the upregulation of TRF2 as 
well as other shelterin components in NBS B-lymphocytes. Unveiling the interaction of 
TRF2 and NBS1 as well as their functions at telomeric ends will partially answer the 
question of why the telomere shortening rate of NBS fibroblasts and NBS B-lymphocytes 
are differentially regulated even though with the same type of gene mutation.   
TRF2 is essential in maintaining the correct structure at telomere termini and preventing 
telomeres from end-to-end fusions (van Steensel, Smogorzewska et al. 1998). It has been 
shown that the dominant negative allele of TRF2 would induce telomere end-to-end 
fusions in metaphase and anaphase cells (van Steensel, Smogorzewska et al. 1998). 
Consistent with previous studies, our result showed that in the absence of functional 
NBS1, NBS fibroblasts that are characterized by dysregulated TRF2 level also showed 
frequent telomere end-to-end fusions. The abnormalities at telomere ends might cause 
abnormal chromosomal segregation, thus leading to aberrant chromosome number 
observed in NBS fibroblasts.   
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4.3 NBS1 deficiency promotes genome instabilities and is implicated in 
carcinogenesis of lymphoid cells 
NBS1 deficiency affects ATM- and ATR-mediated DNA damage signaling pathway. ATM 
and ATR are the two master regulators in DNA damage response network by signaling to 
control cell cycle checkpoints, DNA synthesis, DNA repair and apoptosis (Cimprich and 
Cortez 2008). Therefore, NBS1 deficiency would have an impact on these cellular 
activities, as observed in our study by BrdU assay and FITC Annexin V apoptosis assay. 
Improper response towards DNA damage may allow the continual growth of cells with 
DNA damage rather than being arrested, repaired or even “killed”, thus leading to 
genome instabilities.  
NBS1 deficiency also affects telomere integrity. As observed, NBS1 deficiency leads to 
frequent telomere end-to-end fusions and aneuploidy of cells in NBS fibroblasts, similar 
phenotypes as shown in A-T cells (Pandita 2002). End-to-end fusions might be triggered 
by critically short telomeres which are supposed to lead to replicative senescence. 
However, the process of senescence shares many features with classic DNA DSB 
response (Hezel, Bardeesy et al. 2005) and requires functional DNA damage response 
machinery. NBS1 deficiency affects DNA damage response, therefore may also affect the 
process of replicative senescence and result in telomere end-to-end fusions.  
Dysregulation of both DNA damage response and telomere integrity has been involved in 
cancer initiation and progression (Stewart and Weinberg 2006; Luijsterburg and van 
Attikum 2011). Since NBS1 deficiency leads to abnormalities in both of these two 
aspects, it is natural to link NBS1 deficiency to carcinogenesis. Indeed, NBS patients that 
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are mutated in NBS1 gene are characterized by cancer predisposition, especially to B-cell 
lymphoma and T-cell lymphoblastic lymphoma/leukaemia (The International Nijmegen 
Breakage Syndrome Study Group 2000), indicating that NBS1 deficiency preferentially 
promotes the malignant transformation of B- and T-cell. 
Although fibroblasts are always thought as static entity during cancer initiation and 
progression, recent studies showed that fibroblasts progress together with cancer cells and 
affect the morphology of tumors (Kalluri and Zeisberg 2006; Tsellou and Kiaris 2008). 
Thus, the possibility of NBS1 deficiency in promoting malignant transformation of 
fibroblasts was also tested in vitro by soft agar assay. However, the result suggested that 
NBS1 deficiency does not increase the tumorigenicity of NBS fibroblasts regardless of 
the affected DNA damage response network and compromised telomere integrity.  
Based on our results, we propose that NBS1 deficiency promotes the malignant 
transformation of lymphoid cells, thus leading to lymphoma/leukemia, in two ways. First 
of all, NBS cells with disrupted DNA damage responses license the continual growth and 
survival of cells regardless of genomic abnormalities, which presents a cellular setting 
that predisposes bad cells to sustain, accumulate and perpetuate, leading to 
carcinogenesis. On the other hand, NBS1 deficiency speeds up the process towards 
replicative senescence or senescence-associated apoptosis of NBS cells. Senescence and 
senescence-associated apoptosis process requires proper DNA damage response which is 
compromised due to NBS1 mutation. As a consequence, the natural process of senescence 
and senescence-associated apoptosis would also be affected, leading to unprotected short 
telomeres and genomic instabilities, which finally contributes to carcinogenesis (Figure 
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4.4).   
 
 








5. CONCLUSIONS  
This study examined the roles of NBS1 in protecting genome stability from the aspect of 
maintaining DNA damage response network and telomere integrity. Our work suggests 
that 657del5 mutation of NBS1 gene affects the DNA damage response network in both 
NBS fibroblasts and B-lymphocytes, leading to abnormal cellular responses. Furthermore, 
our work demonstrated that NBS1 gene mutation compromises the telomere integrity. We 
provided solid evidence that NBS fibroblasts have a higher telomere shortening rate in 
vitro in NBS fibroblasts. Moreover, we found that TRF2 expression was upregulated in 
NBS fibroblasts, which is an important clue for studying the underlying mechanism of 
accelerated telomere shortening in future. However, accelerated telomere shortening and 
upregulated TRF2 level were not observed in NBS B-lymphocytes, indicating NBS1 
mutation has different effects at the telomeric ends of fibroblasts and B-lymphocytes.  
Also, our results provided possible explanations to the high incidence of cancer in NBS 
patients. Since dysregulation of DNA damage response network and telomere integrity 
has been implicated in carcinogenesis, we propose that NBS patients are predisposed to 
cancer not only due to defects in repairing DNA damage but also owing to defects in 





6. FUTURE WORK 
6.1 Reintroduction of wild-type NBS1 into NBS fibroblasts and examination of the 
DNA damage response and telomere shortening rate in these cells 
As NBS1 mutation affects DNA damage response and telomere integrity in NBS 
fibroblasts, reintroduction of wild-type NBS1 to reach an expression level that close to 
normal counterparts in NBS fibroblasts may protect cells from these deficiencies. We 
have tried to infect NBS fibroblasts with wild-type NBS1 in our study. However, due to 
the low infection efficiency, the majority of cells died after selection with mammalian 
cell culture selective agent. The alive cells remained were hard to expand and get stable 
overexpressed clones. In the future, we will modify the infection protocol to achieve high 
infection efficiency.  
After we get the stable overexpressed clones with wild-type NBS1, the ATM/ATR 
mediated DNA damage response pathway will be examined. We postulate that ATM and 
ATR as well as their downstream targets will exhibit normal phosphorylation and 
activation in response to Dox treatment after reintroduction of wild-type NBS1. In 
addition, the DNA synthesis status and apoptosis profile will be examined by BrdU assay 
and Annexin V Apoptosis Detection, respectively. Moreover, the wild-type NBS1 
overexpressed cells will be cultured to a long period and the telomere shortening rate will 
be determined and compared with normal fibroblasts using TeloTAGGG Telomere 
Length Assay. We expect that the wild-type NBS1 overexpressed NBS fibroblasts have 
comparative telomere shortening rate with normal fibroblasts. Furthermore, the telomere 
integrity will be examined by metaphase spread analysis. Due to the existence of 
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telomeric end fusions in NBS fibroblasts prior to reintroduction of wild-type NBS1, we 
speculate that telomereic end fusions are still observable in wild-type NBS1 
overexpressed cells.   
6.2 To study the underlying mechanism of NBS1 deficiency-induced TRF2 
upregulation and accelerated telomere shortening in NBS fibroblasts 
As the upregulation of TRF2 and accelerated telomere shortening was observed in NBS 
fibroblasts, we next want to understand how NBS1 deficiency leads to these two 
phenotypes and whether there is a causal relationship between TRF2 upregulation and 
accelerated telomere shortening.  
Two hypotheses will be tested. The first hypothesis is that NBS1 deficiency compromises 
ATM-dependent phosphorylation of TRF2 as well as the dissociation of TRF2 from 
telomeres, resulting in the accumulation of unphosphorylated TRF2 at telomeric ends 
which leads to accelerated telomere shortening. As the first step, the efficiency of the 
recruitment of ATM to telomeres will be determined by confocal immunofluorescence in 
NBS vs. normal fibroblasts. Confocal immunofluorescence will also be employed to 
check the co-localization of TRF2 and ATM. Secondly, the phosphorylation level of 
TRF2 will be examined using western blot. If TRF2 phosphorylation is ATM-dependent, 
we would expect a higher phosphorylation level of TRF2 in normal fibroblasts compared 
to NBS fibroblasts. In the third step, we would transfect normal fibroblasts with a 
dominant negative allele of TRF2 with mutations at the ATM phosphorylation site. 
Confocal immunofluorescence will be performed to compare the TRF2 localization site 
in TRF2 wild-type fibroblasts (NBS1+/+ TRF2+/+) and TRF2 mutant fibroblasts (NBS1+/+ 
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TRF2Δ/Δ). If TRF2 phosphorylation facilitates its dissociation from telomeres, we would 
expect dispersed TRF2 in nucleus but not restricted at telomeric ends in NBS1+/+ TRF2+/+ 
cells, while in NBS1+/+ TRF2Δ/Δ cells, TRF2 mainly localizes at the telomeric ends. This 
step confirms the dissociation of TRF2 from telomeres after its phosp horylation by ATM. 
Lastly, the NBS1+/+ TRF2Δ/Δ fibroblasts will be cultured to a long period. DNA will be 
extracted from cells with different PDLs and subjected to TeloTAGGG Telomere Length 
Assay. The telomere shortening rate of NBS1+/+ TRF2Δ/Δ fibroblasts will be compared to 
that of NBS1+/+ TRF2+/+ cells. If accelerated telomere shortening is also observed in 
NBS1+/+ TRF2Δ/Δ cells, we can establish a model of NBS1 deficiency induced 
accumulation of TRF2 and accelerated telomere shortening as hypothesized.  
The second hypothesis is based on the model of p53-dependent induction of Siah1 and 
ubiquitination of TRF2. As p53 phosphorylation and activation is impaired by NBS1 
deficiency, we hypothesize that Siah1 induction and TRF2 ubiquitination will also be 
affected in NBS fibroblasts, leading to accumulated TRF2 at telomeric ends and 
accelerated telomere shortening. To test this hypothesis, western blot will be used to 
detect the expression level of Siah1 in NBS fibroblasts vs. normal fibroblasts. A lower 
level of Siah1 is expected in NBS fibroblasts compared to that in normal counterparts. To 
prove that the impaired induction of Siah1 is the cause of the upregulated TRF2 level in 
NBS fibroblasts, we will overexpress Siah1 in NBS fibroblasts and check the resulted 
TRF2 level in the second step. Expectedly, we would see a lower TRF2 level in the Siah1 
overexpressed NBS fibroblasts. Lastly, the Siah1 overexpressed fibroblasts will be 
cultured to a long period. DNA will be extracted from cells with different PDLs and 
subjected to TeloTAGGG Telomere Length Assay. The telomere shortening rate of Siah1 
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overexpressed NBS fibroblasts will be compared to untransfected cells. If a lower 
telomere shortening is also observed in Siah1 overexpressed cells, we can conclude that 
the accelerated telomere shortening observed in NBS fibroblasts is due to impaired 
induction of Siah1 and ubiquitination of TRF2.  
6.3 To study the role of the 70 KD C-terminus of NBS1 at telomeric ends in NBS B-
lymphocytes 
As reported, the 70 KD C-terminus of NBS1 is expressed in NBS B-lymphocytes (Maser, 
Zinkel et al. 2001). The 70 KD fragment contains the region that interacts with MRE11 
and is essential for the recruitment of MRE11 from cytoplasm to nucleus to form the 
functional MRN complex (Kobayashi, Antoccia et al. 2004). In the future, we want to 
explore the role of the 70 KD fragment at telomeric ends in NBS B-lymphocytes. To 
confirm the existence of the 70 KD fragment in NBS B-lymphocytes, antibody that 
specifically recognizes the C-terminus of NBS1 will be used in western blot and confocal 
immunofluorescence. Confocal immunofluorescence will be subsequently used to 
visualize the localization of MRE11 and RAD50 in NBS B-lymphocytes. If MRN 
complex could be partially restored in nucleus with the presence of 70 KD fragment, it 
may interact with shelterin complex to exert its roles at telomeric ends. The interaction 
and co-localization of MRN complex and TRF2 will also be examined by co-
immunoprecipitation and confocal immunofluorescence.  
The interaction of MRN complex with TRF2 may be essential to control the TRF2 
cellular level, therefore regulating the telomere shortening rate. Thus, the two hypotheses 
(see section 6.1) will also be examined to reveal the cellular activities of the 70 KD C-
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terminus in NBS B-lymphocytes. In this way, we will have a clear understanding of why 
the same type mutation of NBS1 exerts different effect at telomeric ends in NBS 
fibroblasts and B-lymphocytes.  
6.4 To examine the telomere integrity and malignant transformation of NBS B-
lymphocytes 
NBS patients are prone to B-cell lymphoma (The International Nijmegen Breakage 
Syndrome Study Group 2000), indicating that B cells are prone to malignant 
transformation in the condition of NBS1 mutation. Soft agar assay will be performed to 
test this hypothesis in NBS vs. normal B-lymphocytes. Expectedly, we will observe a 
higher ratio of malignant transformation in NBS B-lymphocytes than that in normal 
counterparts.  
Chromosomal instabilities, such as telomere abnormalities, can promote the malignant 
transformation (Michor 2005). Therefore, metaphase spread will also be performed in 
NBS B-lymphocytes to examine the telomere integrity and find out potential telomere 
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Supplementary Figure 1 
 
 
Figure S1. NBS1 knockdown in human breast cancer cells MCF7. A. Western blot analysis of 
the protein level of NBS1 after knockdown by shRNA (sequence: 5’-AAAACTGCAGAAAAA 
GCAAGCAGATACATGGGATTTTCTCTTGAAAAATCCCATGTATCTGCTTGCGGTGTTTC
GTCCTTTCCACAAG-3’). 2 clones (clone 4 and clone 12) showed similar knockdown effect. α-
tubulin serves as the loading control. B. Western blot analysis of the phosphorylation level of p53 
in MCF7 cells with NBS1 knockdown. Cells were treated with 1 μM Dox for 24 hours. α-tubulin 
serves as the loading control. C. Western blots in B were scanned and quantified by densitometer. 




Supplementary Figure 2 
 
Figure S2. NBS1 deficiency affects the expression level of TOPBP1. Western blot analysis of 
the TOPBP1 protein level in NBS as well as normal fibroblasts. Cells were treated with 1 μM 
Dox and collected at the time points indicated. α-tubulin serves as the loading control.  
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Figure S3. NBS1 deficiency also affects the DNA damage signaling pathway in B-
lymphocytes. Western blot analysis of the phosphorylation level of ATM downstream targets, 
including histone H2AX, p53 and Chk2, in NBS as well as normal B-lymphocytes. Cells were 





NBS1 deﬁciency promotes genome instability by affecting DNA
damage signaling pathway and impairing telomere integrity
Yan Yan Hou, Meng Tiak Toh and Xueying Wang*
Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
Studies revealed that Nijmegen Breakage Syndrome protein 1 (NBS1) plays an important role in maintaining genome stability, but the under-
lying mechanism is controversial and elusive. Our results using clinical samples showed that NBS1 was involved in ataxia-telangiectasia
mutated (ATM)-dependent pathway. NBS1 deﬁciency severely affected the phosphorylation of ATM as well as its downstream targets. BrdU
proliferation assay revealed a delay of NBS cells in inhibiting DNA synthesis after Doxorubicin (Dox) treatment. In addition, under higher
concentrations of Dox, NBS cells exhibited a much lower level of apoptosis compared to their normal counterparts, indicating a resistance
to Dox treatment. Accelerated telomere shortening was also observed in NBS ﬁbroblasts, consistent with an early onset of cellular repli-
cative senescence in vitro. This abnormality may be due to the shelterin protein telomeric binding factor 2 (TRF2) which was found to be
upregulated in NBS ﬁbroblasts. The dysregulation of telomere shortening rate and of TRF2 expression level leads to telomere fusions and
cellular aneuploidy in NBS cells. Collectively, our results suggest a possible mechanism that NBS1 deﬁciency simultaneously affects
ATM-dependent DNA damage signaling and TRF2-regulated telomere maintenance, which synergistically lead to genomic abnormalities.
Copyright © 2011 John Wiley & Sons, Ltd.
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INTRODUCTION
Nijmegen Breakage Syndrome (NBS) is a rare human genetic
disorder characterized by immunodeﬁciency and a strong
predisposition to cancer.1 The underlying gene mutated in
NBS, NBS1, was cloned in 1998 and since then human
NBS1 protein has emerged as a player in the cellular response
to DNA damage, especially to double strand breaks (DSBs).2
In response to DSBs, NBS1 was found to have a close
relationship with another DNA damage-related protein
ATM,3 the gene that is mutated in the ataxia-telangiectasia
(A-T) disease.4
ATM is a member of the phosphoinositol 3-kinase-like
kinase (PIKK) family.5 ATM has a wide range of down-
stream targets, including DNA damage sensors, mediators,
transducers as well as effectors.6 NBS1 has been identiﬁed
as a DNA damage sensor which could be phosphorylated
by ATM in response to ionizing radiation (IR) that generates
DSBs.5 On the other hand, several other studies have placed
NBS1 as an upstream regulator of ATM.7–9
The activation of ATM leads to the phosphorylation of a
plethora of downstream substrates, such as p53, histone
H2AX and Chk2.10 The activation of these downstream
targets results in cellular responses, such as cell cycle
checkpoint controls, DNA damage repair and apoptosis.11
The deﬁciency in either ATM or its downstream substrates
would lead to defective cellular responses. It has been
shown that A-T cells that are deﬁcient in ATM exhibited
defective G1/S, intra-S and G2/M cell cycle transition.6
NBS1, as a downstream target of ATM, is also involved in
the cell cycle arrest and apoptosis pathways. In response to
IR, NBS cells exhibited radio-resistant DNA synthesis, indi-
cating a failure in inducing intra-S checkpoint control.12
Defects in inducing G1 or G2 arrest have also been reported
in NBS cells.13 However, other studies showed normal and
proﬁcient G1 andG2 checkpoint in spite of NBS1 deﬁciency.14
The role of NBS1 in maintaining checkpoint integrity still
remains controversial. Moreover, the inﬂuence of NBS1
deﬁciency on apoptosis is rarely reported and how NBS1
regulates DNA damage induced apoptosis is waiting to
be elucidated.
Besides cell cycle checkpoint and apoptosis, NBS1 also
plays a role in telomere maintenance.15 In yeast, Xrs2, the
functional homolog of NBS1, is involved in telomerase-
dependent telomere synthesis.16 In human, NBS1 is asso-
ciated with telomeres in a cell-cycle regulated manner.17 It
has been reported that NBS ﬁbroblasts showed premature
growth cessation in culture. But how NBS1 deﬁciency leads
to this phenomenon is not well studied. Shelterin complex
serves as another mechanism to maintain telomere integrity
by associating with telomeres and burying the telomeric ends
into t-loops, thus preventing them from being recognized as
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DSBs.18 NBS1 has been shown to interact with one of the
components of shelterin complex, TRF2.19 However, whether
the interaction between NBS1 and TRF2 has an effect on
telomere maintenance is still not known.
This study aims to examine the roles of NBS1 both in
DNA damage signaling pathway and in maintaining telo-
mere integrity. On one hand, we found that NBS1 deﬁciency
affected ATM-mediated DNA damage signaling pathway
and its subsequent cellular events, such as DNA prolifera-
tion and apoptosis. On the other hand, we observed acceler-
ated telomere shortening and an earlier onset of senescence
in NBS cells. Moreover, our group for the ﬁrst time found
that NBS1 deﬁciency is related to an upregulation of
TRF2, which suggests an important clue for studying the
accelerated telomere shortening in the future. This study
also provided evidence that frequent telomere abnormalities
exist in NBS cells. As telomere dysfunction has been impli-
cated in carcinogenesis, this study extends our recognition
of the high incidence of cancers in NBS patients.
MATERIALS AND METHODS
Cells and culture conditions
Cells were obtained from Coriell Cell Repositories (pair1:
AG09309 &GM07166, pair2: GM00637&GM15989, pair3:
AG14725 & GM15814, pair4: GM22671 & GM07078) and
cultured in either MEM or RPMI with 15% FBS, 1% L-
Glutamine, 1% P/S, 1% NEAA and 1% vitamin solution,
and incubated at 37 C under 5% CO2. The NBS cell lines
within each pair are homozygous for a deletion of 5 nucleotides
in exon 6 of NBS1 gene (657del5 mutation).
Western blot and antibodies
Cells were harvested for protein lysate. Brieﬂy, cells were
resuspended in 50mmol/L Tris-HCl (pH 7.4), 250mmol/L
NaCl, 5mmol/L EDTA, and 0.1% NP40 containing prote-
ase and phosphatase inhibitors. Lysates were cleared by
centrifugation at 14,000 rpm for 10min, and samples were
run on SDS-PAGE gels. Western blotting was performed
with the following antibodies: ATM, gH2AX (Novus Biolo-
gicals); ATM pS1981 (Rockland); NBS1, p53, p53 pS15,
Chk2, Chk2 pT68, cleaved caspases3 (Cell Signaling);
PARP, TRF1, POT1 (Abcam); TRF2 (BD Biosciences);
RAP1 (Bethyl Laboratories); Horseradish peroxidase (HRP)-
conjugated mouse anti-GAPDH (Cell Signaling), HRP-
conjugated mouse anti-b actin (Abcam), or mouse anti-a
tubulin (Sigma-Aldrich) were used as loading controls. Immu-
nostaining was detected using ECL Plus Detection Reagent
(GE Healthcare).
FITC Annexin V apoptosis assay
Cells were harvested after 24 hours treatment with Dox under
the concentration of 0.25mM, 0.5mM or 1mM. The apoptosis
level was detected using the protocol as described by the FITC
Annexin V Apoptosis Detection Kit II (BD Pharmingen). The
data was analyzed using BD FACS Diva software.
BrdU assay
Cells were harvested after either 10 hours or 22 hours treat-
ment with 1 mM Dox. The percentage of BrdU+ cells was
determined using the protocol described by the 5-Bromo-
2’-deoxy-uridin labeling and detection kit III (Roche).
Telomere length assay
DNA was extracted from the cells using a genomic puriﬁca-
tion kit (PureLink, Invitrogen). Telomere length analysis was
carried out using a non-radioactive TeloTAGGG Telomere
Length Assay (Roche) as described.
b-Galactosidase staining
Normal and NBS ﬁbroblasts were cultured to the population
doubling level (PDL) indicated. Cells undergoing senes-
cence were detected using the protocol as described by the
b-Galactosidase Staining Kit (US Biological).
Cytogenetic analysis of metaphase spreads
Normal and NBS ﬁbroblasts were cultured to late passages.
Metaphase spreads were prepared as described by the
Jeppesen’s protocol.20
Telomerase activity assay
Telomerase activity was quantiﬁed using Telomeric Repeat
Ampliﬁcation Protocol (TRAP) as described by the TeloEx-
press Quantitative Telomerase Detection Kit (XpressBio).
Telomerase activity in each sample was calculated based on
the comparison with the Ct values of a standard curve gener-
ated from 10-fold dilutions of telomerase control (TC) oligo
with known copy numbers of the telomeric repeats.
RT-PCR
One step RT-PCR was performed using the Qiagen One Step
RT-PCR kit following manufacturer’s protocol. The primers
for TRF2 are: 5’-TGCTCAAGTTCTACTTCCACGA-3’
and 5’-TTGATAGCTGATTCCAGTGGTG-3’. PCR products
were run on 2% agarose gel and viewed under UV Gel Doc
(BioRad).
RESULTS
NBS1 deﬁciency affects ATM phosphorylation and ATM-
dependent phosphorylation of multiple downstream targets
In this study, cells derived from NBS patients who have
typical 657del5 mutation of the NBS1 gene were used. As
controls, normal cells with wild type NBS1 gene were also
employed and paired with NBS cells under the criteria of
age, gender and race for a more reliable comparison. To
determine if NBS1 deﬁciency affects the phosphorylation
of ATM, two NBS ﬁbroblasts as well as their normal coun-
terparts were used (Pair 1 and Pair 2). As shown, the wild
type NBS1 protein was only expressed in normal cells but
not in NBS cells (Figure 1A). Cells were then subjected to
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1mMDox treatment and the phosphorylation level of ATM at
Ser1981 was examined at different time points by western
blot. Results showed that ATM was quickly activated in
normal cells and reached the highest level in 8 hours after
Dox treatment (Figure 1B). However, in NBS cells, ATM
phosphorylation was severely impaired, exhibited by a much
lower level than that in normal counterparts (Figure 1B).
Although ATM phosphorylation level decreased dramatically
in NBS cells, there was still a detectable basal level of phos-
phorylated ATM (Figure 1B) indicating that NBS1 deﬁciency
does not fully abolish ATM phosphorylation.
If NBS1 deﬁciency affects ATM activation, whether the
activation of ATM downstream targets is also affected is the
question that we want to address next. H2AX, p53 and
Chk2 are three important ATM downstream substrates which
are involved in DNA damage responses.10 The phosphoryl-
ation statuses of these three proteins were also examined by
western blot. Results showed that the phosphorylation of
H2AX at Ser139 and phosphorylation of p53 at Ser15 were
also severely affected in NBS cells under 1mMDox treatment
(Figure 1C). In normal cells, these two proteins were quickly
phosphorylated to a high level and the high phosphorylation
level was maintained for all the rest time points detected.
But in NBS cells, the phosphorylation level was signiﬁcantly
decreased (Figure 1C). Moreover, the total level of p53 was
also affected in NBS cells, suggesting a possibility that
NBS1 deﬁciency compromises p53 stability. Surprisingly,
the phosphorylation level of Chk2 at Thr68 was not reduced
in NBS cells, but only exhibited a delay in activation. As
shown, Chk2 was activated and reached a high level within
2 hours in normal cells, but was activated in NBS cells at a
much later time point around 8 hours under 1mM Dox treat-
ment (Figure 1C). Taken together, these results suggest that
NBS1 deﬁciency could affect the phosphorylation of ATM
downstream targets, leading to either a lower phosphorylation
level or a delayed activation of ATM targets.
NBS1 deﬁciency delays inhibition of DNA synthesis after
DNA damages occur
One of the cellular events of DNA damage response is to
inhibit DNA synthesis to stop the propagation of “bad” cells
Figure 1. NBS1 deﬁciency affects ATM phosphorylation and the phosphorylation of multiple ATM downstream targets. A. The expression of NBS1 protein
in NBS ﬁbroblasts as well as in age, race and gender-matched normal cells. The four cell lines were classiﬁed into two pairs, nominated as pair 1 and pair 2.
B. The expression and phosphorylation of ATM. Cells were treated with 1 mM Dox and collected at the time points indicated. The numbers above the blot
indicate the level of pS1981-ATM normalized to the total ATM level measured by densitometer. C. The phosphorylation of ATM downstream targets, includ-
ing H2AX, p53 and Chk2. Cells were treated with 1mM Dox and collected at the time points indicated.
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with DNA lesions. We next investigated the potential roles
of NBS1 in eliciting inhibition of DNA synthesis when
DNA is damaged. Since pair 2 ﬁbroblasts are transformed
with SV40 which would render G1/S checkpoint inactive
and therefore affect the number of cells entering S phase
for DNA synthesis,21 we used additional 2 pairs of B-
lymphocytes (Pair 3 and Pair 4) for analysis of DNA synthe-
sis status. As shown in the western blot, full length NBS1
was only expressed in normal cells but not in NBS cells
(Figure 2A). We performed BrdU incorporation assay to
access the proliferation proﬁle of cells after 1 mM Dox treat-
ment for either 10 or 22 hours. From this result, we found
that the cell proliferation was suppressed after Dox treatment
in both normal and NBS cells, exhibited by the ratio of BrdU+
Dox+ cells to BrdU+Dox- cells less than 1 (Figure 2B).
Although suppression of cell proliferation was observed in
both normal and NBS cells, at 10 hours, NBS cells showed
a lesser degree of arrest than the normal cells, indicated by a
higher BrdU+Dox+ to BrdU+Dox- cells ratio. It was only after
22 hours of Dox treatment, did the NBS cells exhibit a similar
degree of arrest as their normal counterparts (Figure 2B). This
result indicates the suppression of proliferation in NBS cells is
not as efﬁcient as that in normal cells, suggesting a delay in
inhibition of DNA synthesis in NBS cells.
NBS1 deﬁciency affects the initiation of apoptosis
Another cellular event of DNA damage response is to initiate
apoptosis when DNA damage is beyond repair. Cells treated
with different concentrations of Dox for 24 hours were
harvested and subjected to ﬂow cytometry analysis. Results
showed that NBS cells had comparable apoptosis level to nor-
mal cells under lower concentration of Dox treatment. When
the concentration of Dox was increased to a high concentration
of 1mM, normal cells exhibited elevated level of apoptosis. But
apoptosis level in NBS cells remained low as that under lower
concentrations of Dox (Figure 3A, B), indicating that NBS
cells were defective in inducing apoptosis when cells were
exposed to high dosage of Dox. Western analysis of apoptosis
associated markers showed that cleaved caspase3 almost
diminished in NBS cells. However, as a direct downstream
target of caspase3, Poly-ADP-ribose-polymerase (PARP) only
exhibited a minor decrease in its cleaved form in NBS cells
(Figure 3C). This is probably due to the low level of cleaved
caspase3 in NBS cells. The low efﬁciency in cleavage of these
proteins may be responsible for the defects of NBS cells in ini-
tiation of apoptosis under high concentration of Dox treatment.
NBS1 deﬁciency promotes telomere shortening and an
earlier onset of senescence
Premature aging has been observed in NBS ﬁbroblasts
in vitro.22 Premature cellular senescence could be elicited by
accelerated telomere shortening. We therefore asked whether
NBS1 deﬁciency elicits premature aging through regulating
telomere attrition rate. Telomere length of the two pairs of
ﬁbroblasts was tested by the Terminal Restriction Fragment
southern blot. Result showed that the telomere length of
NBS cells was generally shorter than that of age-matched nor-
mal cells. When comparing the telomere attrition rate, we
found that NBS cells showed a higher telomere shortening rate
compared to that in normal cells in vitro (Figure 4A). For each
replication cycle, the telomere shortening rate of NBS cells is
around 30 bp faster than that of its respective normal counter-
parts (Figure 4B). This result strongly indicates that NBS1
plays a role in telomere length maintenance and the deﬁciency
of NBS1 leads to faster telomere attrition. We performed
b-galactosidase assay to study the senescence status of normal
as well as NBS ﬁbroblasts in vitro. Cells were cultured to the
same PDL and stained, and the cells stained blue were counted
as senescent cells. Consistent with the accelerated telomere
shortening, NBS ﬁbroblasts exhibited a signiﬁcantly higher
percentage of cells undergoing senescence compared to nor-
mal cells with the same PDLs (Figure 4C, D). These results
suggest that NBS cells have a larger population of cells with
critically short telomeres.
Figure 2. NBS1 deﬁciency delays inhibition of DNA synthesis after DNA damages occur. A. The expression of NBS1 protein in NBS B-lymphocytes as well
as in age, race and gender-matched normal cells. The four cell lines were classiﬁed into two pairs, nominated as pair 3 and pair 4. B. BrdU incorporation assay.
Cells were seeded onto 96-well plate and after culturing for 2 days, cells were treated with 1 mM Dox and 10mM BrdU at the same time for either 10 or 22
hours. The bar represents the ratio of Dox-treated BrdU+ cells to untreated BrdU+ cells.
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NBS1 deﬁciency does not affect telomerase activity but
upregulates TRF2
Telomere length is maintained by the activity of telomerase.
We questioned whether the accelerated telomere shortening
is due to decreased telomerase activity in NBS cells. By real
time PCR, we found that NBS1-deﬁcient ﬁbroblasts have
comparative telomerase activity as control cells (Figure 5A),
which suggests that the accelerated telomere shortening is
not due to decreased telomerase activity. Shelterin complex
proteins protect the telomere integrity, but it also has been
claimed that these proteins are negative regulators for telo-
mere length.18 We next looked into the different compo-
nents of shelterin complex and found that the cellular level
of TRF2 was upregulated in NBS cells (Figure 5B).
However, the expression of other components, including
TRF1, RAP1 and POT1, did not show obvious changes
(Figure 5C). RT-PCR further showed an upregulation of
TRF2 at mRNA level (Figure 5D). The overabundance of
TRF2 at telomere ends may negatively regulate telomere
length, resulting in accelerated telomere shortening in
NBS cells.
NBS1 deﬁciency promotes genome instability
The accelerated telomere shortening and dysregulation of
shelterin complex components may jeopardize the stability
of telomeres in NBS cells. To evaluate the integrity of telo-
meres of NBS cells, we performed cytogenetic analysis of
metaphase spread to look directly at the chromosome ends.
As shown, prevalent telomere associations were observed
in NBS cells (Figure 6A), exhibited by telomeres of dif-
ferent or the same chromosomes exist in unusually close
proximity. Although very rare, telomere fusions were also
observed in normal cells (Figure 6B). Telomere associations
affect the chromosome separation during mitosis, resulting
in aneuploid cells. We found that most of the normal cells
retain 46 chromosomes during culture in vitro, although
Figure 3. NBS1 deﬁciency affects the initiation of apoptosis. A. FITC Annexin V apoptosis assay. B-lymphocytes were treated with Dox at the indicated
concentrations for 24 hours. The number of apoptotic cells was analyzed by ﬂow cytometry. B. Quantitation of the percentage of apoptosis cells in A. C. Western
blot analysis of apoptosis-related proteins, including cleaved caspase3 and PARP.
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few of them showed abnormal chromosome numbers that
slightly deviate from 46 (Figure 6C). However, NBS cells
showed an average chromosome number of 78 which
signiﬁcantly deviates from the normal chromosome number,
suggesting that the continued replication of NBS cells
in vitro leads to more severe genome instabilities.
DISCUSSION
The NBS1 gene encodes a 95KD protein.23 657del5 muta-
tion of this gene leads to a frame shift and premature termin-
ation at codon 219 which abolishes the expression of the full
length NBS1 protein. It is predicted that the premature
termination would result in the expression of two truncated
proteins, the 26KD N-terminus and the 70KD C-terminus.12
However, only the 26KD fragment, but not the 70KD one, is
found in NBS ﬁbroblasts.24 Our study using the antibody
which recognizes the C-terminal residues of human NBS1
also did not detect the 70KD C-terminus band (data not
shown). It has been proved in Xenopus egg extracts that
the C-terminus of NBS1 is essential to recruit ATM to
damaged DNA where its subsequent autophosphorylation
happens.25 Our results showed in the absence of both full
length NBS1 and its C-terminus, ATM phosphorylation at
Ser1981 was diminished in NBS cells when exposed to
Dox treatment. This result strongly indicates that NBS1
serves as an upstream regulator of ATM. However, NBS
cells still retain a low level of ATM phosphorylation under
Dox treatment. We suggested that ATM autophosphoryla-
tion exists in a low level in cells that are under DNA damage
even without functional NBS1. NBS1 serves as an ampliﬁer
for ATM activity which facilitates ATM to reach a threshold
maximal activity when DNA damages occur.
Besides ATM, the phosphorylation of ATM downstream
targets, including Histone H2AX and p53, was also severely
affected. But NBS1 deﬁciency does not fully abolish the
phosphorylation of these targets, probably due to the exist-
ence of a basal level of ATM phosphorylation. However,
the activation of Chk2 was apparently normal though slightly
delayed in NBS cells under Dox treatment. Like p53, Chk2
could also be phosphorylated by ATM and functions in cell
cycle arrest. The phosphorylation of Chk2 brings its catalytic
domain into the close proximity of another Chk2 molecule
Figure 4. NBS1 deﬁciency leads to accelerated telomere shortening in NBS ﬁbroblasts. A. Measurement of telomere restriction fragment length. Genomic
DNA isolated from normal and NBS ﬁbroblasts at indicated PDLs was analyzed. B. Telomere shortening rate in normal and NBS ﬁbroblasts. Data are mean
S.D. from duplicate experiments. Telomere shortening rate (slope of the regression line) and Spearman’s regression coefﬁcient are indicated. C. Cellular
senescence assay using b-galactosidase staining. Arrows indicate senescent cells. D. Bars represent the percentage of b-galactosidase positive cells. Data
are meanS.D. from 5 images each.
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that allows auto-trans-phosphorylation to occur.26 In NBS1
deﬁcient cells, ATM activation was still present at basal
levels. It could be explained that the basal level of acti-
vated ATM is sufﬁcient to elicit initial phosphorylation
of Chk2 which creates conditions for its following auto-
trans-phosphorylation. But this process may take longer time
than the direct phosphorylation of Chk2 by ATM, thus NBS
cells had a delayed Chk2 phosphorylation.
As an initial response to DNA damages, normal cells with
intact DNA damage signaling pathway would arrest to allow
DNA damage to be repaired.27 Our results showed that the
proliferation rate of NBS cells was not as efﬁciently inhibited
as that of normal cells when they were treated for 10 hours.
But this difference was diminished after 22-hour treatment.
By then, NBS cells showed comparable proliferation rate to
normal cells. This result indicates that NBS1 deﬁciency
may delay the checkpoint control, but does not abolish it.
Using annexin V apoptosis assay, we showed that NBS1
deﬁcient cells exhibited defects in inducing apoptosis under
higher concentration of Dox treatment, while these cells
showed normal apoptosis level under lower concentration
of Dox. The concentration of Dox may be proportional to
the amounts of DNA lesions caused. Under lower concen-
tration, small amount of DNA lesions are generated in cells.
And as shown earlier, although the phosphorylation of ATM
and the phosphorylation events elicited by ATM were either
impaired or delayed in NBS1 deﬁcient cells, there were still
basal levels of activated proteins at later time points. We
speculate that the activated basal-level proteins are sufﬁcient
to encounter the small scale DNA lesions but not enough to
deal with larger scale DNA damage caused by higher con-
centration of Dox. This result suggests that the partially
affected ATM and ATR signaling pathway in NBS cells
could retain the apoptotic event to some degree but could
not fully restore it when under large scale of DNA damage.
Evidence suggests that NBS1 binds to telomeres and is
implicated in telomere length maintenance. Besides NBS1,
many proteins that are crucial for maintaining genome sta-
bility are found associated with human telomeres, including
ATM, the other two subunits of MRN complex, MRE11 and
RAD50, WRN (gene mutated in Werner syndrome) and
BLM (gene mutated in Bloom syndrome).19 The presence
Figure 5. NBS1 deﬁciency upregulates TRF2. A. Real-time PCR for relative telomerase activity in NBS versus normal ﬁbroblasts. B. Western blot analysis of
the TRF2 protein level in NBS and normal ﬁbroblasts. The numbers above the blot indicate its fold difference measured by densitometer with normal cell’s
TRF2 protein level being set at a reference value of 1. C. Western blot analysis of the other shelterin complex proteins in NBS and normal ﬁbroblasts, including
TRF1, POT1 and RAP1. D. RT-PCR analysis of the TRF2 mRNA level in NBS and normal ﬁbroblasts. The numbers above the image indicate its fold difference
measured by densitometer with normal cell’s TRF2 mRNA level being set at a reference value of 1.
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of these proteins at telomeric ends indicates a role of them in
regulating telomere length and maintaining telomere integ-
rity. Mutations of certain telomere associated genes would
cause diseases that are characterized by premature aging, a
clinical symptom that is probably linked to accelerated telo-
mere shortening.28 Our results showed that NBS1 mutation
also led to accelerated telomere shortening. At or around
the same age, NBS cells exhibited shorter telomere length
compared to normal cells. Moreover, we examined the telo-
mere shortening rate in vitro and found that NBS cells had a
higher telomere attrition rate with each population doubling.
The accelerated telomere attrition probably leads to prema-
ture senescence of NBS cells, which was observed in our
study by b-galactosidase assay. AT cells that are mutated
in ATM gene also exhibited accelerated telomere shorten-
ing.29 It has been suggested that ATM phosphorylates
TRF1, a negative regulator of telomere length, thus reduces
the binding of TRF1 to telomeres.30 The reduction in TRF1
binding level at telomeric ends facilitates the assembly of
telomerase to telomere and leads to telomerase-dependent
telomere elongation.30 Therefore, ATM mutation would
exert a negative effect in the telomere elongation, which
may be the cause for accelerated telomere shortening
observed in AT cells. With regard to the close relationship
between NBS1 and ATM, it is possible that NBS1 protects
telomere from accelerated telomere shortening through the
interplay with ATM.
It has been well established that TRF2 expression levels
play an important role in determining telomere shortening
rate.31,32 Like TRF1, TRF2 is also recognized as a negative
regulator of telomere length.33 Overexpression of TRF2
leads to accelerated telomere shortening in vitro and prema-
ture aging in vivo.19 Our results showed that TRF2 was
upregulated at both mRNA and protein levels in NBS1
deﬁcient cells. The upregulation of TRF2 may also contrib-
ute to the accelerated telomere shortening observed in NBS
cells. But how NBS1 deﬁciency leads to upregulation of
TRF2 is not known. In this study, we did not observe the
Figure 6. NBS1 deﬁciency promotes genome instability. A. Metaphase spreads of Pair 1 ﬁbroblasts were stained with antibodies against TRF2 (green) and
visualized by immunoﬂuorescence. DNA was stained with DAPI (blue). Arrows point to telomeric end fusions. The insets (a and b) are representatives of
telomere fusions. B. Bars represent the percentage of cells that are positive with telomere fusions. The total cell number is 25. C. Bars represent the average
number of chromosomes enumerated from the metaphase spreads. Data are meanS.D. from 25 spreads each.
y. y. hou ET AL.
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upregulation in TRF1 level. Although TRF1 and TRF2 have
similar function and binding mode to telomeric DNA, TRF2
plays an important role in T-loop formation that protects
telomere integrity.34 The difference between TRF1 and
TRF2 may be the cause that only TRF2 is affected in the
condition of NBS1 deﬁciency, but not TRF1.
Telomere attrition causes replicative senescence,35 a cellular
process that shares many features with the classic DNA DSB
damage responses.36 NBS1 deﬁciency disrupts the cellular
signaling network, therefore affects the normal process of
cellular senescence and results in aberrant telomere associa-
tions. Our study clearly demonstrated aberrant telomere fusions
in NBS ﬁbroblasts with 657del5 mutation, suggesting genomic
instabilities within these cells.
NBS1 deﬁciency has been implicated in carcinogenesis.
40% of NBS patients developed cancers before the age of
21 years old, especially B-cell lymphoma.1 The high inci-
dence of getting cancer manifests the importance of NBS1
in maintaining genome stability by mediating DNA damage
response and protecting telomere integrity. On one hand,
NBS cells with disrupted DNA damage responses license
the continual growth and survival of cells regardless of
genomic abnormalities, which presents a cellular setting that
predisposes bad cells to sustain, accumulate and perpetuate,
leading to carcinogenesis. On the other hand, accelerated
telomere shortening speeds up the process towards replicative
senescence. But checkpoints defects because of NBS1 deﬁ-
ciency would jeopardize the normal process of cellular
senescence, thus leading to telomere abnormalities. Our work
provides solid evidence that NBS ﬁbroblasts have a higher
telomere shortening rate in vitro. Moreover, we found that
TRF2 expression was upregulated in NBS ﬁbroblasts, which
is an important clue for studying the underlying mechanism
of accelerated telomere shortening in future. Also, our results
from the aspect of telomere abnormalities provided possible
explanations to the high incidence of cancer in NBS patients.
Since telomere dysfunction has also been implicated in
carcinogenesis, we propose that NBS patients are predisposed
to cancer not only due to defects in repairing DNA damage
but also because of defects in maintaining telomere integrity.
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